Devices and methods for delivering a lyophilized medicament

ABSTRACT

An apparatus includes a housing, an actuator, a lock mechanism, and a medicament container. The lock mechanism selectively engages a portion of the housing such that (1) the lock mechanism is maintained in a substantially fixed position when the housing is in a first orientation and (2) the lock mechanism is removable from the housing when the housing is in a second orientation. The medicament container is moved in a proximal direction when the lock mechanism is removed from the housing to mix a first medicament portion contained within the medicament container with a second medicament portion contained within the medicament container. The actuator can be moved from a first position to a second position when the lock mechanism is removed from the housing to release energy stored within an energy storage member such that the medicament container is moved in a distal direction.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application benefit of priority to U.S. Provisional ApplicationSer. No. 62/137,606, entitled “Devices and Methods for Injecting aLyophilized Medicament,” filed Mar. 24, 2015, which is incorporatedherein by reference in its entirety.

BACKGROUND

The embodiments described herein relate generally to medicament deliverydevices, and more particularly to a medicament delivery device formixing a medicament, priming a medicament container, and delivering themedicament into a body of a patient.

Exposure to certain substances, such as, for example, peanuts,shellfish, bee venom, certain drugs, toxins, and the like, can causeallergic reactions in some individuals. Such allergic reactions can, attimes, lead to anaphylactic shock, which can cause a sharp drop in bloodpressure, hives, and/or severe airway constriction. Accordingly,responding rapidly to mitigate the effects from such exposures canprevent injury and/or death. For example, in certain situations, aninjection of epinephrine (i.e., adrenaline) can provide substantialand/or complete relief from the allergic reaction. In other situations,for example, an injection of an antidote to a toxin can greatly reduceand/or eliminate the harm potentially caused by the exposure. Similarly,an injection of glucagon can reduce and/or eliminate the harmpotentially caused by reduced blood glucose levels in individuals whosuffer from diabetes (e.g., a hypoglycemic emergency).

Because emergency medical facilities are not always available when anindividual is suffering from a medical condition, some individuals carryan auto-injector, a rescue inhaler, or the like to rapidlyself-administer a medicament in response to such medical conditions.Some known auto-injectors include a vial containing a liquid medicamentand a spring loaded needle to automatically penetrate the user's skinand inject the medicament. The storage of certain medicaments in aliquid form, however, can result in a shorter shelf life and/or anunstable medicament. Accordingly, some known auto-injectors include avial containing a first medicament that is separated from a secondmedicament. Such auto-injectors are often referred to as “wet/dry”auto-injectors, because one medicament is often a liquid (e.g., water oranother diluent) and the other medicament can be substantially solid ordry (e.g., lyophilized glucagon powder). Lyophilization is also known as“freeze drying.” In use, the first medicament and the second medicamentmust be mixed prior to injection.

Some known wet/dry injectors, however, require that the user manuallyactuate a mixing mechanism prior to injection (e.g., by twisting aportion of the device to complete the mixing step). Such configurationscan, however, result in incomplete mixing and/or an injection occurringwithout mixing. In addition, the operation of some known wet/drydelivery systems includes manually inserting the needle into the skinprior to activation and subsequent medicament delivery. The operation ofsuch configurations may also include separately attaching a needle toprepare the device for injection, resulting in a delay in delivery ofthe medicament. Moreover, such configurations can be complicated, makingthem difficult for a user to operate during an emergency or by anindividual without medical training.

Some known wet/dry injectors employ a single mechanism to automaticallymix and inject the medicaments contained therein. Because the mixingoperation is dependent on the injection operation in suchconfigurations, however, the medicament can be injected prior to thecompletion of the mixing operation and/or prior to the injector beingproperly positioned for the injection operation.

Some known wet/dry injectors are configured such that a user canmanually vent and/or purge a portion of air included in the medicamentcontainer (e.g., mixed with or a part of the glucagon powder). In someinstances, such known injectors are generally oriented in apredetermined manner (e.g., with the needle end facing upward) duringthe mixing process and/or prior to injection to facilitate the ventingprocess (also referred to as “priming”). Such injectors, however, lack alocking mechanism and/or a compliance mechanism to prevent initiation ofthe mixing process when the injector is not properly oriented. Moreover,known some injectors are not configured to prevent an injection eventfrom occurring prior to mixing the medicament and/or otherwise ventingor priming a portion of air in the medicament container. Therefore, inmany known auto-injectors, the venting process can be performedincorrectly or incompletely.

Procedures for using some known medicament delivery devices, includingmedical injectors and inhalers, include rapidly moving (or shaking) thedevice to enhance the mixing or otherwise assist in preparing the dosefor delivery. Such known devices, however, do not include any mechanismfor providing feedback regarding whether the medicament has beenproperly shaken or mixed.

Thus, a need exists for improved medicament delivery devices to improvethe procedures for mixing a medicament, priming a medicament container,and delivering the medicament. Specifically, a need exists for animproved auto-injector that can separately store two or more medicamentsor medicament portions and that can mix the medicaments or medicamentportions and vent excess air from the medicament container prior toinjecting the medicament.

SUMMARY

Medicament delivery devices for mixing a medicament and delivering themedicament are described herein. In some embodiments, an apparatusincludes a housing, a safety member, and a lock member. The housing isconfigured to contain at least a portion of a medicament container, andincludes a housing surface defining a lock chamber. The safety member iscoupled to the housing and can be moved relative to the housing betweena first position and a second position. The safety member is configuredto limit delivery of a contents of the medicament container when thesafety member is in the first position. An outer surface of the safetymember is disposed outside of the housing. A lock protrusion of thesafety member is disposed within the lock chamber of the housing whenthe safety member is in the first position. The lock protrusion isdisposed outside of the lock chamber when the safety member is in thesecond position. The lock member is disposed within the lock chamber ofthe housing and is configured to move along the housing surface when anorientation of the longitudinal axis of the medicament containerchanges. The lock member is positioned in contact with the lockprotrusion of the safety member to limit movement of the safety memberfrom the first position to the second position when the longitudinalaxis of the medicament container is in a first orientation. The lockmember is spaced apart from the lock protrusion when the longitudinalaxis of the medicament container is in a second orientation.

In some embodiments, an apparatus includes a housing and an electroniccircuit system. The housing has an interior wall defining a volumewithin which at least a portion of a medicament container can bedisposed. The medicament container can move within the volume to conveya medicament when a force is exerted on a portion of the medicamentcontainer. The electronic circuit system is coupled to the housing, andincludes a processor, an output device, and a sensor. The sensor isconfigured to produce a signal received by the processor that isassociated with at least one of an orientation of the housing or amovement of the housing. The electronic circuit system configured toproduce an electronic output via the output device in response to thesignal.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of a medicament delivery deviceaccording to an embodiment in a first configuration and a firstorientation.

FIG. 2 is a schematic illustration of the medicament delivery deviceshown in FIG. 1 in a first configuration and a second orientation.

FIG. 3 is a schematic illustration of the medicament delivery deviceshown in FIG. 1 in a second configuration and a third orientation.

FIG. 4 is a schematic illustration of a medicament delivery deviceaccording to an embodiment in a first configuration and a firstorientation.

FIG. 5 is a schematic illustration of the medicament delivery deviceshown in FIG. 4 in a first configuration and a second orientation.

FIG. 6 is a schematic illustration of the medicament delivery deviceshown in FIG. 4 in a second configuration and a third orientation.

FIGS. 7-9 are schematic illustrations of a medicament delivery deviceaccording to an embodiment in a first configuration, a secondconfiguration, and a third configuration, respectively.

FIG. 10 is a cross-section view of the medicament delivery device shownin FIG. 8 taken along the line X-X in FIG. 8.

FIG. 11 is a perspective view of a medicament delivery device accordingto an embodiment in a first configuration.

FIGS. 12 and 13 are a front view and a rear view, respectively, of themedicament delivery device of FIG. 11 in a second configuration.

FIGS. 14 and 15 are a front view and a top view, respectively, of themedicament delivery device of FIG. 11 in a third configuration.

FIGS. 16 and 17 are a front perspective view and a rear perspectiveview, respectively, of a housing included in the medicament deliverydevice of FIG. 11.

FIGS. 18 and 19 a bottom view and a top view, respectively, of thehousing of FIG. 16.

FIG. 20 is a cross-sectional view of the housing of FIG. 16 taken alongthe line X₂-X₂ in FIG. 18.

FIG. 21 is a cross-sectional view of the housing of FIG. 16 taken alongthe line X₃-X₃ in FIG. 19.

FIG. 22 is a cross-sectional view of a portion of the medicamentdelivery device of FIG. 11 taken along the line X₁-X₁ in FIG. 15.

FIGS. 23 and 24 are a front perspective view and a bottom perspectiveview, respectively, of a proximal cap included in the medicamentdelivery device of FIG. 11.

FIG. 25 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the second configuration (i.e., with the case removed and thesafety lock in the “locked” position) taken along the line X₁-X₁ in FIG.15.

FIG. 26 is an enlarged view of a portion of the medicament deliverydevice of FIG. 1 identified by the region Z₁ in FIG. 25.

FIG. 27 is a front view of a portion of the medicament delivery deviceof FIG. 11 in the second configuration.

FIGS. 28 and 29 are perspective views of a system actuator included inthe medicament delivery device of FIG. 11.

FIG. 30 is a bottom view of the system actuator of FIG. 28.

FIG. 31 is a top view of the medicament delivery device of FIG. 11.

FIG. 32 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the second configuration (i.e., with the case removed and thesafety lock in the “locked” position) taken along the line X₄-X₄ in FIG.31.

FIG. 33 is an enlarged view of a portion of the medicament deliverydevice of FIG. 1 identified by the region Z₂ in FIG. 32.

FIGS. 34 and 35 are a front view and a top view, respectively, of amedicament container included in the medicament delivery device of FIG.11.

FIG. 36 is a cross-sectional view of the medicament container of FIG. 34taken along the line X₅-X₅ in FIG. 35.

FIGS. 37 and 38 are a perspective view and a top view, respectively, ofa carrier included in the medicament delivery device of FIG. 11.

FIG. 39 is a cross-sectional view of the carrier of FIG. 27 taken alongthe line X₆-X₆ in FIG. 28.

FIGS. 40 and 41 are a front view and a rear view of an electroniccircuit system included in the medicament delivery device of FIG. 11.

FIG. 42 is a top view of the medicament delivery device of FIG. 11.

FIG. 43 is a cross-sectional view of a portion of the medicamentdelivery device of FIG. 11 in the second configuration (i.e., with thecase removed and the safety lock in the “locked” position) taken alongthe line X₇-X₇ in FIG. 42.

FIGS. 44-46 are enlarged views of a portion of the medicament deliverydevice of FIG. 11 identified by the region Z₃ in FIG. 43, in a secondconfiguration, a third configuration (i.e., with the safety lockremoved), and sixth configuration (i.e., after actuation of theinjection event), respectively.

FIGS. 47 and 48 are a front perspective view and a top perspective view,respectively, of a case included in the medicament delivery device ofFIG. 11.

FIG. 49 is a front view of the medicament delivery device of FIG. 11 inthe first configuration.

FIG. 50 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the first configuration, taken along the line X₈-X₈ in FIG.49.

FIGS. 51 and 52 are a perspective view and a top view, respectively, ofa safety lock included in the medicament delivery device of FIG. 11.

FIG. 53 is a cross-sectional view of the safety lock of FIG. 51 takenalong the line X₉-X₉ in FIG. 52.

FIG. 54 is an enlarged view of a portion of the safety lock of FIG. 51identified by the region Z₄ in FIG. 53.

FIG. 55 is a front view of the medicament delivery device of FIG. 11 inthe second configuration (i.e., with the case removed and the safetylock in the “locked” position).

FIG. 56 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the second configuration, taken along the line X₁-X₁ in FIG.15.

FIG. 57 is a front view of the medicament delivery device of FIG. 11 inthe third configuration (i.e., with the safety lock removed to initiatemixing).

FIG. 58 is a cross-sectional view of the medicament delivery device ofFIG. 1 in the third configuration, taken along the line X₁-X₁ in FIG.15.

FIG. 59 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the fourth configuration (i.e., at the beginning of themixing operation, with the needle in fluid communication with themedicament container), taken along the line X₁-X₁ in FIG. 15.

FIG. 60 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the fifth configuration (i.e., at completion of the mixingoperation), taken along the line X₁-X₁ in FIG. 15.

FIG. 61 is a front view of the medicament delivery device of FIG. 11 inthe sixth configuration (i.e., after actuation of the base, with theneedle insertion completed).

FIG. 62 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the sixth configuration, taken along the line X₁-X₁ in FIG.15.

FIG. 63 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the seventh configuration (i.e., after completion of theinjection operation), taken along the line X₁-X₁ in FIG. 15.

FIG. 64 is a front view of the medicament delivery device of FIG. 11 inan eighth configuration (i.e., after retraction of the needle).

FIG. 65 is a cross-sectional view of the medicament delivery device ofFIG. 11 in the eighth configuration, taken along the line X₁-X₁ in FIG.15.

DETAILED DESCRIPTION

Medicament delivery devices for mixing and/or delivering a medicamentare described herein. In some embodiments, an apparatus includes anapparatus includes a housing, a safety member, and a lock member. Thehousing is configured to contain at least a portion of a medicamentcontainer, and includes a housing surface defining a lock chamber. Thesafety member is coupled to the housing and can be moved relative to thehousing between a first position and a second position. The safetymember is configured to limit delivery of a contents of the medicamentcontainer when the safety member is in the first position. An outersurface of the safety member is disposed outside of the housing. A lockprotrusion of the safety member is disposed within the lock chamber ofthe housing when the safety member is in the first position. The lockprotrusion is disposed outside of the lock chamber when the safetymember is in the second position. The lock member is disposed within thelock chamber of the housing and is configured to move along the housingsurface when an orientation of the longitudinal axis of the medicamentcontainer changes. The lock member is positioned in contact with thelock protrusion of the safety member to limit movement of the safetymember from the first position to the second position when thelongitudinal axis of the medicament container is in a first orientation.The lock member is spaced apart from the lock protrusion when thelongitudinal axis of the medicament container is in a secondorientation.

In some embodiments, the housing surface that defines the lock chamberis angularly offset from a longitudinal axis of the medicamentcontainer.

In some embodiments, the apparatus is an auto-injector that includes amedicament container within which a first medicament is storedseparately from a second medicament. The first medicament can be adiluent (e.g., a liquid, such as water) and the second medicament caninclude an active agent. In some embodiments, the second medicament canbe substantially solid or dry (e.g., glucagon powder, to form a wet/dryinjector). In other embodiments, the second medicament can be liquid. Insuch embodiments, the contents of the medicament container delivered caninclude a gas from one of the medicament volumes within the medicamentcontainer. In other embodiments, the contents can include a portion ofthe first medicament, the second medicament, or both.

In some embodiments, an apparatus includes a housing, an energy storagemember, and a safety member. The housing is configured to contain atleast a portion of a medicament container. The energy storage member isdisposed within the housing, and is configured to produce a force toconvey a contents of the medicament container when the energy storagemember is actuated to release a potential energy stored therein. Thesafety member is coupled to the housing. A first portion of the safetymember is configured to actuate the energy storage member when thesafety member is moved relative to the housing between a first positionand a second position. A second portion of the safety member isconfigured to engage a lock member within the housing to limit movementof the safety member from the first position to the second position whenthe longitudinal axis of the medicament container is in a firstorientation. The second portion of the safety member is spaced apartfrom the lock member when the longitudinal axis of the medicamentcontainer is in a second orientation.

In some embodiments, an apparatus includes a safety member configured tobe coupled to a housing of a medicament delivery device. The safetymember can be moved relative to the housing between a first position anda second position. A lock portion of the safety member is configured tobe disposed within a lock chamber defined by the housing when the safetymember is in the first position. The lock portion is configured toengage a lock member within the lock chamber to limit movement of thesafety member from the first position to the second position when alongitudinal axis of the housing is in a first orientation. The lockportion is spaced apart from the lock member when the longitudinal axisof the medicament container is in a second orientation. An actuationportion of the safety member is configured to actuate an energy storagemember of the medicament delivery device when the safety member is movedfrom the first position to the second position. The energy storagemember produces a force to convey a contents from a medicament containerof the medicament delivery device when the energy storage member isactuated.

In some embodiments, an apparatus includes a housing, an energy storagemember, a medicament container assembly, and a flange. The housing hasan interior wall defining a first portion of a boundary of a gaschamber. The energy storage member is configured to produce apressurized gas within the gas chamber when the energy storage member isactuated to release a potential energy stored therein. The medicamentcontainer assembly is disposed within the housing, and includes acontainer body and an elastomeric member disposed within the containerbody. A surface of the elastomeric member defines a second portion ofthe boundary of the gas chamber. The medicament container assemblyincludes a delivery member coupled to a distal end portion of thecontainer body. The flange is coupled to the container body. A proximalsurface of the flange defines a third portion of the boundary of the gaschamber. An edge surface of the flange is in sliding contact with theinterior wall of the housing. The flange and the container body areconfigured to move together within the housing from a first position toa second position in response to actuation of the energy storage member.A ratio of an area of the proximal surface of the flange to the surfaceof the elastomeric member is such that the elastomeric member remains ina fixed position within the container body when the flange and thecontainer body move within the housing from the first position to thesecond position. In some embodiments, the ratio is greater than abouttwo.

In some embodiments, any of the medicament delivery devices shown herecan include an electronic circuit system that outputs instructions,wireless signals, or other electronic outputs in response to the usermanipulating the device. In some embodiments, an apparatus includes ahousing and an electronic circuit system. The housing has an interiorwall defining a volume within which at least a portion of a medicamentcontainer can be disposed. The medicament container can move within thevolume to convey a medicament when a force is exerted on a portion ofthe medicament container. The electronic circuit system is coupled tothe housing, and includes a processor, an output device, and a sensor.The sensor is configured to produce a signal received by the processorthat is associated with at least one of an orientation of the housing ora movement of the housing. The electronic circuit system configured toproduce an electronic output via the output device in response to thesignal.

In some embodiments, the sensor can be configured to produce a signalassociated with a mixing of the contents within a medicament container.For example, in some embodiments, the sensor can be an optical sensorconfigured to detect the presence of solid particles (e.g., any unmixedlyophilized medicament) within the medicament container. In otherembodiments, the electronic circuit system can produce a count-downtimer or indication of time remaining until the medicament is mixed(e.g., the time remaining during which the medicament container shouldbe shaken).

In some embodiments, an apparatus includes a housing, an actuator, alock mechanism, and a medicament container. The actuator is at leastpartially disposed in the housing and is configured to be moved from afirst position to a second position relative to the housing to releaseenergy stored within an energy storage member. The lock mechanism isremovably coupled to the housing to selectively maintain the actuator inthe first position. The lock mechanism selectively engages a portion ofthe housing such that (1) the lock mechanism is maintained in asubstantially fixed position when the housing is in a first orientation,and (2) the lock mechanism is removable from the housing when thehousing is in a second orientation.

In some embodiments, the medicament container contains a firstmedicament portion and a second medicament portion. The medicamentcontainer is configured to be moved in a proximal direction within thehousing in response to a first force when the lock mechanism is removedfrom the housing to mix the first medicament portion with the secondmedicament portion. The actuator is configured to be moved from thefirst position to the second position after the lock mechanism isremoved from the housing. The medicament container is configured to movein a distal direction within the housing in response to a second forceassociated with the release of energy from the energy storage member.

As used in this specification, the singular forms “a,” “an” and “the”include plural referents unless the context clearly dictates otherwise.Thus, for example, the term “a member” is intended to mean a singlemember or a combination of members, “a material” is intended to mean oneor more materials, or a combination thereof.

As used herein, the term “medicament” includes any constituent of atherapeutic substance. A medicament can include such constituentsregardless of their state of matter (e.g., solid, liquid or gas).Moreover, a medicament can include the multiple constituents that can beincluded in a therapeutic substance in a mixed state, in an unmixedstate and/or in a partially mixed state. A medicament can include boththe active constituents and inert constituents of a therapeuticsubstance. Accordingly, as used herein, a medicament can includenon-active constituents such as, water, colorant or the like.

The term “about” when used in connection with a referenced numericindication means the referenced numeric indication plus or minus up to10 percent of that referenced numeric indication. For example, “about100” means from 90 to 110.

As used herein, the words “proximal” and “distal” refer to directioncloser to and away from, respectively, an operator of the medicaldevice. Thus, for example, the end of the medicament delivery devicecontacting the patient's body would be the distal end of the medicamentdelivery device, while the end opposite the distal end would be theproximal end of the medicament delivery device. As another example, thedistal end portion of a medical injector is the end from which a needleor delivery member extends during the delivery event.

The term “parallel” is used herein to describe a relationship betweentwo geometric constructions (e.g., two lines, two planes, a line and aplane, or the like) in which the two geometric constructions arenon-intersecting as they extend substantially to infinity. For example,as used herein, a planar surface (i.e., a two-dimensional surface) issaid to be parallel to a line when every point along the line is spacedapart from the nearest portion of the surface by a substantially equaldistance. Similarly, a first line (or axis) is said to be parallel to asecond line (or axis) when the first line and the second line do notintersect as they extend to infinity. Two geometric constructions aredescribed herein as being “parallel” or “substantially parallel” to eachother when they are nominally parallel to each other, such as forexample, when they are parallel to each other within a tolerance. Suchtolerances can include, for example, manufacturing tolerances,measurement tolerances or the like.

The terms “perpendicular,” “orthogonal,” and “normal” are used herein todescribe a relationship between two geometric constructions (e.g., twolines, two planes, a line and a plane, or the like) in which the twogeometric constructions intersect at an angle of approximately 90degrees within at least one plane. For example, as used herein, a line(or axis) is said to be normal to a planar surface when the line and aportion of the planar surface intersect at an angle of approximately 90degrees within the planar surface. Two geometric constructions aredescribed herein as being, for example, “perpendicular” or“substantially perpendicular” to each other when they are nominallyperpendicular to each other, such as for example, when they areperpendicular to each other within a tolerance. Such tolerances caninclude, for example, manufacturing tolerances, measurement tolerancesor the like.

Similarly, geometric terms, such as “parallel,” “perpendicular,”“cylindrical,” “square,” “conical,” or “frusto-conical” are not intendedto require absolute mathematical precision, unless the context indicatesotherwise. Instead, such geometric terms allow for variations due tomanufacturing or equivalent functions. For example, if an element isdescribed as “conical” or “generally conical,” a component that is notprecisely conical (e.g., one that is slightly oblong) is stillencompassed by this description.

FIGS. 1-3 are schematic illustrations of a medicament delivery device2000 according to an embodiment in various configurations andorientations. The orientation of the device 2000 (and any of the otherdevices shown herein) can be described with reference to an upwardvertical axis A_(V), which is an axis having a direction opposite thatof the direction of gravity. The medicament delivery device 2000includes a housing 2100, a safety member 2700, and a lock member 2730.The housing 2000 can be any suitable structure within which at least aportion of a medicament container 2210 can be disposed. The housing 2100can be, for example, a housing of a single-use auto-injector withinwhich the medicament container 2210 is fully disposed. In otherembodiments, the housing 2100 can be a housing of a reusableauto-injector, within which multiple different medicament containers canbe disposed and actuated as a part of a dosage regimen. In yet otherembodiments, the housing 2100 can be a housing of a pen injector. In yetother embodiments, the housing 2100 can be an inhaler housing withinwhich a distal end portion of the medicament container 2210 is disposed.

The housing 2100 (and any of the housings described herein) can beconstructed from any suitable materials, such as plastic (includingthermoplastics such as cyclic olefin copolymers). In some embodiments,the housing 2100 can be monolithically constructed. In otherembodiments, the housing 2100 (and any of the housing described herein)can be constructed of multiple components that can be coupled together(such as the housing 1100 described below).

As shown, the housing 2100 defines a volume within which a portion ofthe medicament container 2210 can be disposed. The medicament container2210 defines a longitudinal axis A_(MC), and includes a delivery member2240 (e.g., a needle, a nozzle, a mouthpiece, or a valve) through whichthe contents 2228 contained therein can be conveyed. The medicamentcontainer 2210 can be any suitable medicament container, such as, forexample a pre-filled cartridge, a vial, an ampule, a pre-filled syringe,or the like. In some embodiments, the medicament container 2210 can be acontainer within which a first medicament is stored separately from asecond medicament. The first medicament can be a diluent (e.g., aliquid, such as water) and the second medicament can include an activeagent. In some such embodiments, the second medicament can besubstantially solid or dry (e.g., glucagon powder, to form a wet/dryinjector). In other embodiments, the second medicament can be liquid. Instill other embodiments, the medicament container 2210 can be a drugcanister containing a propellant and a medicament, and the housing 2100can be an inhaler housing. The contents 2228 can a liquid medicament, agas from one of the medicament volumes within the medicament container(e.g., excess air from the lyophilized medicament), a combination of aliquid and a gas, or a propellant.

The housing 2100 includes a housing surface 2152 that defines a lockchamber 2155 within the housing 2100. As described in more detail below,the lock chamber 2155 contains the lock member 2730. In someembodiments, the housing surface 2152 is angularly offset from thelongitudinal axis A_(MC) of the medicament container 2210 when themedicament container 2210 is disposed within the housing 2100. Similarlystated, in some embodiments, a tangent line of the housing surface 2152and the longitudinal axis A_(MC) of the medicament container 2210 forman angle greater than zero degrees and less than 90 degrees.Specifically, as shown in FIG. 1, in some embodiments, the tangent lineof the housing surface 2152 and the longitudinal axis A_(MC) form anangle θ that is non-parallel with and not normal to the longitudinalaxis A_(MC). In this manner, as described below, the lock member 2730can move along the housing surface 2152 when the medicament container2210 is within a desired orientation range or when the medicamentcontainer 2210 changes orientation relative to the upward vertical axisA_(V).

In some embodiments, the lock chamber 2155 can be defined by more thanone housing surface. For example, in some embodiments, the housing caninclude multiple, discontinuous surfaces that collectively define thelock chamber 2155 such that the movement of the lock member 2730 followsa desired path when the medicament container 2210 changes orientationrelative to the upward vertical axis A_(V). For example, as shown inFIGS. 1-3, in some embodiments, the housing 2100 can include a secondhousing surface 2156 that, along with the first housing surface 2152,defines the lock chamber 2155. In some embodiments, the second housingsurface 2156 can be opposite to and/or substantially parallel to thefirst housing surface 2152. In other embodiments, the second housingsurface 2156 can form a non-zero angle (i.e., can be non-parallel to)the first housing surface 2152. In this manner, the lock member can movealong either of the first housing surface 2152 or the second housingsurface 2156 when the orientation of the longitudinal axis L_(MC) of themedicament container changes.

The safety member 2700 is movably coupled to the housing 2100, and isconfigured to limit the delivery of the contents 2228 from themedicament container 2210. As shown in FIG. 1, the safety member 2700includes an outer surface 2713 and a lock protrusion (or lock portion)2706. The safety member 2700 is coupled to the housing 2100 such thatthe outer surface 2713 is disposed outside of the housing 2100. Thus, inuse, the safety member 2700 can be manipulated via the outer surface2713 to be moved relative to the housing 2100 to enable delivery of thecontents 2228 from the medicament container 2210. In some embodiments,the outer surface 2713 can include ribs, protrusions, or a surfacetexture to facilitate a user manipulating the safety member 2700. Insome embodiments, the outer surface 2713 can include visual indicia(symbols, arrows, text, etc.).

The lock protrusion 2706 is disposed within the lock chamber 2155 of thehousing 2100 when the safety member is in a first position, as shown inFIG. 1. In this manner, depending on the orientation of the housing 2100and/or the medicament container 2210, the lock protrusion 2706 can be incontact with the lock member 2730 to limit movement of the safety member2700 relative to the housing 2100. This arrangement allows for thesafety member 2700 to be removed only when the housing 2100 and/or themedicament container 2210 are within a desired orientation range. Insome embodiments, for example, the lock protrusion 2706 can include arecessed portion 2708 (or “hook”) that receives the lock member 2730when the longitudinal axis A_(MC) of the medicament container 2210 is ina desired orientation.

In use, the safety member 2700 can be moved between a first position(see FIG. 1) and a second position (see FIG. 3). Moreover, the device2000 (including the housing 2100 and the longitudinal axis A_(MC) of themedicament container 2210) can be moved between at least twoorientations. Said another way, the device 2000 can be rotated such thatthe longitudinal axis A_(MC) of the medicament container 2210 rotatesrelative to the upward vertical axis A_(V). FIG. 1 shows the device 2000having the safety member 2700 in the first position (i.e., attached tothe housing 2100 such that the lock protrusion 2706 is disposed withinthe lock chamber 2155) and in a first orientation. Specifically, themedicament container 2210 is pointed downwards (i.e., the longitudinalaxis A_(MC) of the medicament container 2210 forms an angle of about 180degrees with the upward vertical axis A_(V)). When the medicamentcontainer 2210 and/or housing 2100 are in the first orientation, thelock protrusion 2706 is in contact with the lock member 2730, and thelock member 2730 is retained within the lock chamber 2155. Thisarrangement prevents the safety member 2700 from being moved to thesecond position (as indicated by the arrow AAA in FIG. 1).

FIG. 2 shows the device 2000 having the safety member 2700 in the firstposition (i.e., attached to the housing 2100 such that the lockprotrusion 2706 is disposed within the lock chamber 2155) and in asecond orientation. Specifically, the orientation of the medicamentcontainer 2210 has changed such that the longitudinal axis A_(MC) of themedicament container 2210 forms an angle α with the upward vertical axisA_(V). As shown in FIG. 2, the lock member 2730 moves along the housingsurface 2152 when the orientation of the longitudinal axis A_(MC) of themedicament container 2210 changes such that the lock member 2730 is nolonger in contact with the lock protrusion 2706. Thus, when the device2000 is in the second orientation, the safety member 2700 can be movedfrom its first position to its second position. Similarly stated, thelock member 2730 is disengaged from the lock protrusion 2706, and thesafety member 2700 is no longer retained by the lock member 2730.

FIG. 3 shows the device 2000 having the safety member 2700 in the secondposition (i.e., attached to the housing 2100 but with the lockprotrusion 2706 no longer within the lock chamber 2155) and in a thirdorientation. Specifically, the orientation of the medicament container2210 has changed such that the longitudinal axis A_(MC) of themedicament container 2210 is pointed directly upwards (i.e., it forms anangle of about zero degrees with the upward vertical axis A_(V)). Asshown by the arrow AAA in FIG. 3, the safety member 2700 can be movedrelative to the housing 2100 to enable delivery of the contents 2228 ofthe medicament container 2210 (shown by the arrow BBB). Thus, when thedevice 2000 is in a range of orientations, including at least the secondorientation and the third orientation, the safety member 2700 can bemoved from its first position to its second position. Further, uponremoval of the safety member 2700, a force F can be exerted on themedicament container 2210 (e.g. via a movable member 2260) to deliver atleast a portion of the contents 2228.

In some embodiments, the contents 2228 can include a gas from within themedicament container 2210, and the orientation range can be within ±15degrees from the upward vertical axis A_(V). In this manner, themedicament container 2210 can be properly primed (or bled) when thedelivery member 2240 is pointing in a generally upward direction toallow the gas to escape. Because the safety member 2700 cannot beremoved when the delivery member 2240 is pointing downward (e.g., FIG.1), an orientation in which the gas cannot easily escape, thearrangement of the safety member 2700 described above prevents theinitiation of the priming step. The orientation range can be anysuitable orientation range. For example, in some embodiments, theorientation range can be within ±25 degrees from the upward verticalaxis A_(V), within ±30 degrees from the upward vertical axis A_(V),within ±35 degrees from the upward vertical axis A_(V), or within ±40degrees from the upward vertical axis A_(V).

Although the safety member 2700 is shown as being coupled to the housing2100 when in its second position (e.g., FIG. 3), in other embodiments,the safety member 2700 can be removed from the housing 2100 when in itssecond position.

Although the housing 2100 is shown as including a housing surface 2152that is substantially linear (or flat), in other embodiments, thehousing surface 2152 can have any suitable shape. For example, in someembodiments, the housing surface 2152 can have a conical shape, and thelock member 2730 can have a spherical shape, such that the lock member2730 can roll along the conical surface 2152.

The force F can be applied by any suitable means. For example, in someembodiments, the user can apply the force manually, such as by squeezingthe housing 2100, depressing the medicament container 2210, pushing apiston against an elastomeric member (not shown) within the medicamentcontainer 2210, or the like. In other embodiments, the force F can beapplied by an energy storage member (not shown) disposed within thehousing 2100. In some such embodiments, the safety member can include anactuation portion configured to actuate the energy storage member whenthe safety member is moved.

For example, FIGS. 4-6 show a medicament delivery device 3000 accordingto an embodiment in various configurations and orientations. Theorientation of the device 3000 (and any of the other devices shownherein) can be described with reference to an upward vertical axisA_(V), which is an axis having a direction opposite that of thedirection of gravity. The medicament delivery device 3000 includes ahousing 3100, a safety member 3700, a lock member 3730, and an energystorage member 3580. The housing 3000 can be any suitable structurewithin which at least a portion of a medicament container 3210 can bedisposed. The housing 3100 can be, for example, a housing of asingle-use auto-injector within which the medicament container 3210 isfully disposed. In other embodiments, the housing 3100 can be a housingof a reusable auto-injector, within which multiple different medicamentcontainers can be disposed and actuated as a part of a dosage regimen.In yet other embodiments, the housing 3100 can be a housing of a peninjector. In yet other embodiments, the housing 3100 can be an inhalerhousing within which a distal end portion of the medicament container3210 is disposed.

As shown, the housing 3100 defines a volume within which a portion ofthe medicament container 3210 can be disposed. The medicament container3210 defines a longitudinal axis A_(MC), and includes a delivery member3240 through which the contents 3228 contained therein can be conveyed.The medicament container 3210 can be any suitable medicament container,such as, for example a pre-filled cartridge, a vial, an ampule, apre-filled syringe, or the like. In some embodiments, the medicamentcontainer 3210 can be a container within which a first medicament isstored separately from a second medicament. The first medicament can bea diluent (e.g., a liquid, such as water) and the second medicament caninclude an active agent. In some such embodiments, the second medicamentcan be substantially solid or dry (e.g., glucagon powder, to form awet/dry injector). In other embodiments, the second medicament can beliquid. In still other embodiments, the medicament container 3210 can bea drug canister containing a propellant and a medicament, and thehousing 3100 can be an inhaler housing. The contents 3228 can a liquidmedicament, a gas from one of the medicament volumes within themedicament container, a combination of a liquid and a gas, or apropellant.

In some embodiments, the lock member 3730 can be disposed within thehousing 3100. In such embodiments, the lock member 3730 can move withinthe housing 3100 to selectively engage the safety member 3700, asdescribed in more detail below. In other embodiments, the lock member3730 can be coupled to the housing 3100 (e.g., on an outer surface ofthe housing), and can move relative to the housing 3100 to selectivelyengage the safety member 3700.

The energy storage member 3580 is disposed within the housing 3100, andis configured to produce a force F (see FIG. 6) to convey the contents3228 of the medicament container 3210 when the energy storage member3580 is actuated to release a potential energy stored therein. Theenergy storage member 3580 can be any suitable member or device thatstores potential energy and, when actuated, releases the energy toproduce a force. For example, the energy storage member can be any of agas container, a chemical energy storage member, a spring, or anelectrical energy storage member.

The safety member 3700 is movably coupled to the housing 3100, and isconfigured to actuate the energy storage member 3580 when the safetymember 3700 is moved relative to the housing 3100 between a firstposition (FIG. 4) and a second position (FIG. 6). As shown, the safetymember 3700 includes a first portion 3715 and a second portion 3706. Thefirst portion 3715 engages a movable member 3260 (e.g., a carrier, aretention member, or the like) when the safety member 3700 is in one ofthe first position or the second position. When the safety member 3700is moved from the first position (FIG. 4) to the second position (FIG.6), the first portion 3715 actuates the movable member 3260 and/or theenergy storage member 3580 to produce the force F, as shown in FIG. 6.

The second portion 3706 of the safety member 3700 can be engaged withthe lock member 3730 when the safety member 3700 is in a first positionto limit movement of the safety member 3700 relative to the housing3100, as shown in FIG. 4. Moreover, depending on the orientation of thehousing 3100 and/or the medicament container 3210, the second portion3706 can be either be in contact with the lock member 3730 to limitmovement of the safety member 3700 relative to the housing 3100, or canbe spaced apart from the lock member 3730. This arrangement allows forthe safety member 3700 to be removed only when the housing 3100 and/orthe medicament container 3210 are within a desired orientation range. Insome embodiments, for example, the second portion 3706 can include arecessed portion (not shown) that receives the lock member 3730 when thelongitudinal axis A_(MC) of the medicament container 3210 is in adesired orientation.

In use, the safety member 3700 can be moved between a first position(see FIG. 4) and a second position (see FIG. 6, as shown by the arrowCCC). Moreover, the device 3000 (including the housing 3100 and thelongitudinal axis A_(MC) of the medicament container 3210) can be movedbetween at least two orientations. Said another way, the device 3000 canbe rotated such that the longitudinal axis A_(MC) of the medicamentcontainer 3210 rotates relative to the upward vertical axis A_(V). FIG.4 shows the device 3000 having the safety member 3700 in the firstposition (i.e., attached to the housing 3100) and in a firstorientation. Specifically, the medicament container 3210 is pointeddownwards (i.e., the longitudinal axis A_(MC) of the medicamentcontainer 3210 forms an angle of about 180 degrees with the upwardvertical axis A_(V)). When the medicament container 3210 and/or housing3100 are in the first orientation, the second portion 3706 is in contactwith the lock member 3730. This arrangement prevents the safety member3700 from being moved to the second position (as indicated by the arrowCCC in FIG. 4).

FIG. 5 shows the device 3000 having the safety member 3700 in the firstposition (i.e., attached to the housing 3100) and in a secondorientation. Specifically, the orientation of the medicament container3210 has changed such that the longitudinal axis A_(MC) of themedicament container 3210 forms an angle α with the upward vertical axisA_(V). As shown in FIG. 3, the lock member 3730 moves (as shown by thearrow DDD in FIG. 5) when the orientation of the longitudinal axisA_(MC) of the medicament container 3210 changes such that the lockmember 3730 is no longer in contact with the second portion 3706. Thus,when the device 3000 is in the second orientation, the safety member3700 can be moved from its first position to its second position.

FIG. 6 shows the device 3000 having the safety member 3700 in the secondposition, and with the device 3000 in a third orientation. Specifically,the orientation of the medicament container 3210 has changed such thatthe longitudinal axis A_(MC) of the medicament container 3210 is pointeddirectly upwards (i.e., it forms an angle of about zero degrees with theupward vertical axis A_(V)). As shown by the arrow CCC in FIG. 6, thesafety member 3700 can be moved relative to the housing 3100 to actuatethe energy storage member 3580. This, in turn, produces the force F todeliver of the contents 3228 of the medicament container 3210 (shown bythe arrow EEE). Thus, when the device 3000 is in a range oforientations, including at least the second orientation and the thirdorientation, the safety member 3700 can be moved from its first positionto its second position. Further, upon removal of the safety member 3700,a force F produced by the energy storage member 3580 can be exerted onthe medicament container 3210 (e.g. via a movable member 3260) todeliver at least a portion of the contents 3228.

In some embodiments, the contents 3228 can include a gas from within themedicament container 3210, and the orientation range can be within ±15degrees from the upward vertical axis A_(V). In this manner, themedicament container 3210 can be properly primed (or bled) when thedelivery member 3240 is pointing in a generally upward direction toallow the gas to escape. Because the safety member 3700 cannot beremoved when the delivery member 3240 is pointing downward (e.g., FIG.1), an orientation in which the gas cannot easily escape, thearrangement of the safety member 3700 described above prevents theinitiation of the priming step. The orientation range can be anysuitable orientation range. For example, in some embodiments, theorientation range can be within ±25 degrees from the upward verticalaxis A_(V), within ±30 degrees from the upward vertical axis A_(V),within ±35 degrees from the upward vertical axis A_(V), or within ±40degrees from the upward vertical axis A_(V).

Although the safety member 3700 is shown as being coupled to the housing3100 when in its second position (e.g., FIG. 6), in other embodiments,the safety member 3700 can be removed from the housing 3100 when in itssecond position.

In some embodiments, the housing 3100 can define a lock chamber (notshown) within which the lock member 3730 is disposed. The lock chambercan be similar to the lock chamber 2155 shown and described above.

In some embodiments, a medical injector can include a fluid system toproduce a force to move a medicament container and/or to move anelastomeric member within the medicament container to deliver amedicament therein. Such fluid systems can be hydraulic or gas-based.Moreover, in some embodiments, such medical injectors can be devoid of arigid member that transfers the force produced by the pressurized fluidonto the surface of the medicament container and/or elastomeric member.Said another way, in some embodiments, a medical injector can be a“pistonless” design that does not require a rigid member to apply forceonto the fluid and/or elastomeric member in order to deliver fluid fromthe medicament container. Such arrangements can produce a more compact(smaller) form factor when compared to devices that employ a rigidmember to deliver the fluid from the medicament container.

As one example, FIGS. 7-10 show a medicament delivery device 4000according to an embodiment in various configurations. The medicamentdelivery device 4000 includes a housing 4100, a medicament containerassembly 4200, a flange 4230, and an energy storage member 4580. Thehousing 4000 can be any suitable structure within which at least aportion of the medicament container 4210 can be disposed. The housing4100 can be, for example, a housing of an auto-injector within which themedicament container 4210 is fully disposed. In other embodiments, thehousing 4100 can be a housing of a reusable auto-injector, within whichmultiple different medicament containers can be disposed and actuated asa part of a dosage regimen. In yet other embodiments, the housing 4100can be a housing of a pen injector.

As shown, the housing 4100 includes an interior wall 4140 that defines afirst portion of a boundary of a gas chamber 4141. The gas chamber 4141is a volume within which a portion of the pressurized gas from theenergy storage member 4580 is conveyed when the energy storage member4580 is actuated. As described in more detail below, the gas chamber4141 is also the volume within which a portion of the medicamentcontainer 4210 is movably disposed.

The medicament container assembly 4200 includes a container body 4210,an elastomeric member 4220, and a delivery member 4240 (coupled to adistal end portion 4212). The delivery member 4240 is the structurethrough which the contents contained within the container body 4210 canbe conveyed. The delivery member 4240 can be any suitable member, suchas a needle, a nozzle, or a valve, through which the contents containedof the container body 4210 can be conveyed.

The elastomeric member 4220 is disposed within the container body 4210and defines a portion of the medicament volume within the container body4210. The elastomeric member 4220 forms a substantially fluid-tight sealwith the container body 4210 such that when a force is exerted on theelastomeric member 4220 that is sufficient to move the elastomericmember 4220 within the container body 4210, the contents therein will beconveyed via the delivery member 4240. As shown, the elastomeric member4220 includes a surface 4222 that defines a second portion of theboundary of the gas chamber 4141.

The elastomeric member 4220 can be of any design or formulation suitablefor contact with the medicament (e.g., a diluent, a liquid medicament,or a lyophilized medicament). For example, the elastomeric member 4220can be formulated to minimize any reduction in the efficacy of themedicament that may result from contact (either direct or indirect)between the elastomeric member 4220 and the medicament. In someembodiments, the elastomeric member 4220 can be made from and/or caninclude butyl rubber, such as chlorobutyl rubber, bromobutyl rubber,and/or the like. In some embodiments, the elastomeric member 4220 can beformulated to minimize any leaching or out-gassing of compositions thatmay have an undesired effect on the medicament.

The medicament container 4210 can be any suitable medicament container,such as, for example a pre-filled cartridge, a vial, an ampule, apre-filled syringe, a Crystal Zenith® container, or the like. In someembodiments, the medicament container 4210 can be a container withinwhich a first medicament is stored separately from a second medicament.The first medicament can be a diluent (e.g., a liquid, such as water)and the second medicament can include an active agent. In some suchembodiments, the second medicament can be substantially solid or dry(e.g., glucagon powder, to form a wet/dry injector). In otherembodiments, the second medicament can be liquid.

The flange 4230 is coupled to the container body 4210, and includes aproximal surface 4231 and an edge surface 4232. The proximal surface4231 defines a third portion of the boundary of the gas chamber 4141. Inthis manner, the interior wall 4140 of the housing 4100, the surface4222 of the elastomeric member 4220, and the proximal surface 4231 ofthe flange 4230 are exposed to the pressurized gas (and thus, the samepressure) during normal use. The edge surface 4232 of the flange 4230 isin sliding contact with the interior wall 4140. Thus, in use, the flange4230 and the container body 4210 move together within the housing 4100from a first position (FIG. 7) to a second position (FIGS. 8 and 9) inresponse to actuation of the energy storage member 4580.

Moreover, as shown in FIG. 10, the area A₁ of the surface 4222 of theelastomeric member 4220 is sized such that when the pressurized gas isconveyed into the gas chamber 4141, the resulting force exerted on thesurface 4222 is insufficient to move the elastomeric member 4220 withinthe container body 4210 when the flange 4230 and the container body 4210are moving from the first position to the second position. Similarlystated, a ratio of an area A₂ of the proximal surface 4231 of the flange4230 (including the area A₁) to the area A₁ of the surface 4222 of theelastomeric member 4220 is such that the elastomeric member 4220 remainsin a fixed position within the container body 4210 when the flange 4230and the container body 4201 move within the housing 4100 from the firstposition to the second position, as shown by the arrow FFF in FIG. 8.When the medicament container assembly 4200 reaches the second position(FIG. 8), a portion of the container body 4210 engages a surface,protrusion, or end-stop. The continued increase of the gas pressure (duein part to the fixed volume of the gas chamber 4141) then causes theelastomeric member 4220 to move, as shown by the arrow GGG in FIG. 9.

In some embodiments, the area ratio is greater than about 2. In otherembodiments, the area ratio is greater than about 2.5. In otherembodiments, the area ratio is greater than about 3.0.

In some embodiments, the flange 4230 can include a valve, bore, or othermechanism to release the gas pressure from within the gas chamber 4141.In this manner, the flange 4230 and the container assembly 4200 can bemoved proximally (e.g., retracted) after delivery of the medicament. Insome embodiments, for example, the flange 4230 can define a bore that iscontinuously opened, and that releases the gas pressure during theinsertion and injection event. The bore can be sized such that theamount of pressure released from the gas chamber 4141 does not impedethe insertion and injection operations.

FIGS. 11-65 show various views of a medical injector 1000 according toan embodiment in various different configurations (or stages ofoperation). FIG. 11 is a perspective view of the medical injector 1000(also referred to herein as “medicament delivery device” or “device”) ina first configuration (i.e., prior to use). FIGS. 12 and 13 are a frontview and a rear view, respectively, of the medical injector 1000 in asecond configuration (i.e., with the case 1180 removed). FIGS. 14 and 15are a front view and a top view, respectively, of the medical injector1000 in a third configuration (i.e., with the safety lock removed toinitiate mixing). The medical injector 1000 includes a housing 1100 (seee.g., FIGS. 16-26), a system actuator assembly 1500 (see e.g., FIGS.27-33), a medicament container assembly 1200 including a medicamentcontainer 1210 (see e.g., FIGS. 34-36), a carrier 1260 (FIGS. 37-39), anelectronic circuit system 1900 (see e.g., FIGS. 40-46), a cover 1180(see e.g., FIGS. 47-10), and a safety lock (or mixing actuator, seee.g., FIGS. 51-54, also referred to as a mixing actuator). A discussionof the components of the medical injector 1000 will be followed by adiscussion of the operation of the medical injector 1000 correspondingto FIGS. 55-65.

As shown in FIGS. 16-26, the housing 1100 has a proximal end portion1101 and a distal end portion 1102, and an outer surface 1105 and aninner surface 1130. The housing 1100 defines a pair of status indicatorapertures 1107 disposed on a front side 1106 and a rear side 1110 of thehousing 1100 (e.g., opposite sides of the housing 1100), which areconfigured to allow a patient to monitor the status and/or contents ofthe medicament container 1200 contained within the housing 1100. Forexample, by visually inspecting the status indicator apertures 1107, apatient can determine whether the medicament container 1200 contains amedicament and/or whether the medicament has been dispensed. As shown inFIG. 16, the housing 1100 defines a set of audible output deviceopenings 1108. As described in further detail herein, the housing 1100is configured to house the electronic circuit system 1900 such that anaudible output device 1930 (see e.g., FIGS. 40, 41 and 50) issubstantially aligned with the audible output device openings 1108.Thus, during use, the audible output device openings 1108 can allowsound waves produced by the audible output device 1930 to passtherethrough.

As shown in FIGS. 16 and 17, the distal end portion 1102 of the housing1100 includes a set of alignment protrusions 1114 and defines a set ofrecess 1111 and a LED opening 1115. The alignment protrusions 1114extend from the outer surface 1105 on the front side 1106 and the rearside 1110 of the housing 1100. In some embodiments, the alignmentprotrusion 1114 on the first side 1106 of the housing 1100 issubstantially opposite the alignment protrusion 1114 on the second side1110 of the housing 1100. In other embodiments, the alignmentprotrusions 1114 need not be aligned and/or opposite each other. Thealignment protrusions 1114 are configured to be matingly inserted into acorresponding alignment notch 1703 of the safety lock 1700 (alsoreferred to as the mixing actuator, see e.g., FIGS. 12 and 13). As shownin FIG. 16, the alignment protrusion 1114 disposed on the front side1106 of the housing 1100 defines the LED opening 1115. As described infurther detail herein, the housing 1100 is configured to housing theelectronic circuit system 1900 such that a set of LEDs 1940 are alignedwith and at least partially extend through the LED opening 1115 (seee.g., FIG. 12). Thus, a user can verify a status and/or receive aninstruction associated with the medical injector 1000 by visuallyinspecting the LEDs 1940 via the LED opening 1115.

As shown in FIGS. 16 and 17, the outer surface 1105 of the housing 1100defines the recesses 1111 on the front side 1106 and the rear side 1130of the housing 1100. The recesses 1111 are configured to receive aportion of a base 1510 included in the system actuator assembly 1500.Similarly, the recesses 1111 each define a set of actuator retentionnotches 1112 and a carrier lock aperture 1113. More specifically, theactuator retention notches 1112 disposed on the front side 1106 of thehousing 1100 include, for example, a pair of distal actuator retentionnotches 1112 and a proximal retention notch 1112. The pair of distalactuator retention notches 1112 are configured to receive acorresponding pair of retention members 1519 of the base 1510 (see e.g.,FIG. 29) when the system actuator assembly 1500 is in a first positionrelative to the housing 1100. The proximal actuator retention recess1112 is configured to receive the corresponding retention member 1519 ofthe base 1510 when the system actuator assembly 1500 is in a secondposition relative to the housing 1100. As described in further detailherein, the housing 1100 can house the medicament container assembly1200 such that a lock portion 1275 of the carrier 1260 (see e.g., FIG.37) is at least partially disposed in the carrier lock aperture 1113when the carrier 1260 is in a first position relative to the housing1100 (e.g., prior to insertion and injection, for example, when thedevice 1000 is in the first or second configuration).

In some embodiments, the actuator retention notches 1112 have a taperedproximal sidewall and a non-tapered distal sidewall. This allows theactuator retention notches 1112 to receive the retention members 1519 ofthe base 1510 to allow the base 1510 to move proximally relative to thehousing 1100 (e.g., to actuate the injector 1000), but to substantiallyprohibit the base 1510 from moving distally relative to the housing1100. Said another way, the distal actuator retention notches 1112 areconfigured to prevent the base 1510 from moving distally when the systemactuator 1500 is in its first position and the proximal actuatorretention notches 1112 are configured to prevent the base 1510 frommoving distally when the system actuator 1500 is in its second (oractuated) position. Thus, the actuator retention notches 1112 and theretention members 1519 of the actuator cooperatively limit movement ofthe system actuator 1500 to prevent undesirable movement of the systemactuator 1500 after the medical injector 1000 is actuated. Specifically,the retention member 1519 prevent the base 1510 from being removed fromthe housing 1100 (e.g., pulled distally from the housing) when thesafety lock 1700 is removed. The arrangement of the second side 1130 ofthe housing 1100 is substantially similar to the first side 1106 of thehousing 1100 and thus, is not described in further detail herein.

As shown in FIGS. 18 and 19, the distal end portion 1102 of the housing1100 defines a set of lock mechanism openings 1121, a lock rod opening1122, a needle opening 1123, a system activation opening 1124, and anelectronic activation opening 1125. The set of lock mechanism openings1121 receives, at least partially, a lock portion 1705 included in thesafety lock (or mixing actuator) 1700 (see e.g., FIGS. 25, 26, and51-54) when the safety lock 1700 is coupled to the housing 1100.Similarly, the lock rod opening 1122 receives a portion of a lock rod1715 included in the safety lock 1700 (see e.g., FIGS. 25, 26, and51-54) when the safety lock 1700 is coupled to the housing 1100. Theneedle opening 1105 is the opening through which the needle 1240 isdisposed (see e.g., FIGS. 25 and 26) when the medical injector 1000 isactuated. The system activation opening 1124 receives a release rod 1530extending from a proximal surface 1511 of the base 1510 of the systemactuator assembly 1500 (see e.g., FIGS. 25 and 27) and allows the systemactuator 1500 to be moved in a proximal direction relative to thehousing 1100. In addition, the system activation opening 1124 receives abattery isolation protrusion 1185 of the cover 1180 (see e.g., FIGS. 48and 50) when the cover 1180 is disposed about at least a portion of thehousing 1100. The electronic activation opening 1125 receives anelectronic actuator protrusion 1520 of the base 1510 (see e.g., FIGS. 28and 29) and allows the system actuator 1500 to engage a portion of theelectronic circuit system 1900, as described in further detail herein.

As shown in FIGS. 18-22, the inner surface of the housing 1100 defines agas cavity 1132, a medicament cavity 1141, and a mixing actuator cavity1142. The gas cavity 1132 is configured to receive a set of retentionmembers 1163 included in a proximal cap 1160, a gas container 1580, anda portion of the system actuator assembly 1500 (e.g., a release member1550 and a spring 1565, as shown in FIG. 25), as described in furtherdetail herein. The gas cavity 1132 is at least partially separated fromthe medicament cavity 1141 and the mixing actuator cavity 1142.Specifically, the inner surface 1130 includes and/or forms a sidewall1131 and a distal wall 1133, which collectively define at least aportion of the gas cavity 1132. As shown in FIGS. 19-22, the gas cavity1132 is in fluid communication with the medicament cavity 1141 via a gaspassageway 1104 defined, for example, by a proximal surface 1103 of thehousing 1100, as described in further detail herein. The distal wall1133 defines an opening 1134 that is configured to receive a portion ofthe release member 1550 (see e.g., FIG. 25). More particularly, a distalend portion 1552 of the release member 1550 can be maintained in contactwith the distal wall 1133 prior to using the medical injector 1000.Thus, prior to actuating the medical injector 1000 the release member1550 is substantially prevented from moving in a proximal directionrelative to the housing 1100, as described in further detail herein. Asdescribed in further detail herein, inner surface 1130 of the housing1100 includes and/or forms a set of actuator protrusions 1135 that areconfigured to limit a transverse or lateral movement of the release rod1530 while allowing the release rod 1530 to move substantially freely inan axial direction (e.g., proximal and/or distal direction).

The medicament cavity 1141 is configured to receive the medicamentcontainer assembly 1200 and a mixing protrusion 1162 of the proximal cap1160 (see e.g., FIGS. 23-25). As shown in FIGS. 20-22 at least a portionof the medicament cavity 1141 is separated from the gas cavity 1132 andthe mixing actuator cavity 1142. More specifically, the inner surface1130 of the housing 1100 includes and/or forms the sidewall 1131, whichseparates the medicament cavity 1141 from the gas cavity 1132, and asidewall 1140, which separates at least a portion of the medicamentcavity 1141 from the mixing actuator cavity 1142. As described infurther detail herein, the medicament container assembly 1200 is movablewithin the medicament cavity 1141 in the proximal direction and in thedistal direction. Moreover, the medicament container 1210 included inthe medicament container assembly 1200 includes a proximal flange 1230with an outer seal member 1235 configured to form a substantially fluidtight seal with the inner surface 1130 of the housing 1100 defining themedicament cavity 1141 (see e.g., FIG. 25). The medicament containerassembly 1200 also includes an inner seal member 1236 disposed betweenan inner surface of the flange 1230 and the medicament container 1210.The inner seal member 1236 form a substantially fluid tight seal withthe inner surface of the flange 1230 defining the medicament cavity 1141(see e.g., FIG. 25).

The mixing actuator cavity 1142 is configured to receive a mixingactuator rod 1290, a bias member 1295 (e.g., a spring or the like), anda portion of the carrier 1260. More particularly, the mixing actuatorrod 1290 of the medicament container assembly 1290 is fixedly disposedin the mixing actuator cavity 1142 and extends from a lock mechanismportion 1150 disposed at or near the distal end portion 1102 of thehousing 1100 to a mixing rod recess 1164 defined by the proximal cap1160. A mixing portion 1261 of the carrier 1260 is disposed about themixing actuator rod 1290 and is movable within the mixing actuatorcavity 1142 along a length of the mixing actuator rod 1290 in responseto a force produced by the bias member 1295, as described in furtherdetail herein.

As shown in FIGS. 20-22, the inner surface 1130 of the housing 1100includes and/or forms the lock portion 1150 and defines a pair ofmedicament container recesses 1145 disposed on opposite sides on theinner surface 1130. The medicament container recesses 1145 areconfigured to increase a distance between opposite sides of the innersurface 1130 to allow a portion of the medicament container 1210 to movetherebetween, as described in further detail herein. The lock portion1150 defines a recess 1151, a basket 1152, and a set of openings 1153.The recess 1151 is configured to receive a corresponding portion of themixing actuator rod 1290 (see e.g., FIGS. 25 and 26). In someembodiments, the portion of the mixing actuator rod 1290 (e.g., a distalend portion 1292) can be fixedly disposed in the recess 1151 andmaintained therein via an adhesive, a fastener, a friction fit, a snapfit, an ultrasonic weld, and/or the like or combination thereof. Moreparticularly, the distal end portion 1292 of the mixing actuator rod1290 includes a flange 1293 configured to be disposed in the recess 1151defined by the lock portion 1150. The set of openings 1153 areconfigured to receive a lock portion 1705 of the safety lock 1700. Asdescribed in further detail herein, the lock portion 1150 of the housing1100 can receive a lock member (or lock ball) 1730 that can beselectively positioned in the basket 1152 such that the lock portion1150 of the housing 1100, the mixing actuator rod 1290 of the medicamentcontainer assembly 1200, and the safety lock 1700 collectively maintainthe safety lock 1700 in a fixed position relative to the housing 1100,which in turn, prevents the medical injector 1000 from being actuated(see e.g., FIGS. 25 and 26). In particular, as described in more detailbelow, the lock member 1730 is positioned to limit movement of thesafety lock (or mixing actuator) 1700 relative to the housing 1100 whenthe medical injector 1000 is outside of a desired orientation range(e.g., when the medical injector 1000 is not within approximately 30degrees of being vertical, with the needle tip pointed upwards).

As described above, the proximal end portion 1101 of the housing 1100includes and/or is otherwise coupled to a proximal cap 1160 (see e.g.,FIGS. 22-24). The proximal cap 1160 includes the retention members 1163and the mixing protrusion 1162, and defines a seal recess 1161 and themixing rod recess 1164. As shown in FIG. 22, the proximal cap 1160 iscoupled to the proximal surface 1103 of the housing 1100. In someembodiments, the proximal cap 1103 is fixedly coupled to the proximalsurface 1103 via, for example, ultrasonic welding, adhesive, fasteners,and/or the like or a combination thereof. Moreover, a seal member 1170is disposed in the seal recess 1161 and is configured to form asubstantially fluid tight seal between the proximal cap 1160 and theproximal surface 1103 of the housing 1100.

The retention members 1163 of the proximal cap 1160 are configured toreceive and/or retain the gas container 1580 that contains a pressurizedgas, as shown in FIG. 25. When the medical injector 1000 is actuated,pressurized gas from the gas container 1580 is conveyed from the gascavity 1132 to the medicament cavity 1141 via the gas passageway 1104(described above). Said another way, the gas passageway 1104 places thegas cavity 1132 in fluid communication with the medicament cavity 1141.The mixing protrusion 1162 extends from a surface of the proximal cap1160 and is configured to engage a portion of the medicament containerassembly 1200 (e.g., an elastomeric member 1220 disposed in themedicament container 1210), as described in further detail herein. Themixing rod recess 1164 receives a proximal end portion 1291 of themixing actuator rod 1290. In some embodiments, the proximal end portion1291 of the mixing actuator rod 1290 can be fixedly disposed in themixing rod recess 1164 via a friction fit, a fastener, an adhesive,ultrasonic welding, and/or the like or a combination thereof. Thus, insome embodiments, the proximal end portion 1291 of the mixing actuatorrod 1290 can be fixedly coupled to the proximal cap 1160 and the distalend portion 1292 can be fixedly coupled to the lock portion 1150 of thehousing 1100 such that the mixing actuator rod 1290 substantiallytraverses the mixing actuator cavity 1142.

FIGS. 27-39 show the medicament container assembly 1200, the systemactuator assembly 1500, and the proximal cap 1160 of the medicalinjector 1000. As shown in FIGS. 27-33, the system actuator assembly1500 includes the base 1510, a release member 1550, and a spring 1565.As shown in FIGS. 28-30, the base 1510 of the system actuator assembly1500 includes a proximal surface 1511, a distal surface 1512. The base1510 defines a set of lock mechanism openings 1513, a needle opening1514 with a safety lock rod portion 1515, and a battery isolationprotrusion opening 1516. The set of lock mechanism openings 1513receive, at least partially, the lock portion 1705 included in thesafety lock 1700 (see e.g., FIGS. 25, 26, and 51-54) when the safetylock 1700 is coupled to the housing 1100. Similarly, the safety lock rodportion 1515 of the needle opening 1514 receives a portion of the lockrod 1715 of the safety lock 1700 (see e.g., FIGS. 25, 26, and 51-54)when the safety lock 1700 is coupled to the housing 1100. The needleopening 1514 also receives and/or allows the needle 1240, an engagementportion 1710 of the safety lock 1700, and a needle sheath 1280 to bedisposed and/or pass therethrough, as described in further detailherein. The battery isolation protrusion opening 1516 receives thebattery isolation protrusion 1185 of the cover 1180 and an electronicactivation protrusion 1720 of the safety lock 1700, as described infurther detail herein.

The proximal surface 1511 of the base 1510 includes and/or is coupled tothe release rod 1530, a set of tabs 1517, and an electronic actuatorprotrusion 1520. More specifically, in this embodiment, the base 1510includes two tabs 1517 monolithically formed with the base 1510, each ofwhich is disposed on opposite sides of the base 1510. As shown in FIG.29, each tab 1517 includes a set of the retention members 1519. Theretention members 1519 are configured to selective engage the actuatorretention notches 1112 of the housing 1100, as described in detailabove. The electronic actuator protrusion 1520 extends from the proximalsurface 1511 of the base 1510 and is movably received in the electronicactivation opening 1125 (see FIG. 16) of the housing 1100. Theelectronic actuator protrusion 1520 is configured to selectively engagea portion of the electronic circuit system 1900 to actuate at least aportion thereof, as described in further detail herein.

The release rod 1530 extends from the proximal surface 1511 of the base1510 to selectively engage a portion of the release member 1550 when thebase 1510 is moved relative to the housing 1100, as described in furtherdetail herein. Although the base 1510 and the release rod 1530 are shownas being monolithically constructed to form a portion of the systemactuator assembly 1500, in other embodiments, the system actuatorassembly 1500 can include a base that is constructed separately from(and later joined to) a release member. A portion of the release rod1530 is movably disposed within the system activation opening 1124defined by the housing 1100 (see e.g., FIGS. 25 and 32). Said anotherway, the release rod 1530 extends from the base 1510 and through thesystem activation opening 1124 defined by the housing 1100 to allow therelease rod 1530 to move within the housing 1100 from a first positionto a second position, as described in further detail herein.

The release rod 1530 includes a proximal end portion 1531 and a distalend portion 1532 and defines a channel 1533 between an engagementsurface 1534 and the distal end portion 1532 (see e.g., FIGS. 25, and27-29). The channel 1533 receives a portion of the electronic circuitsystem 1900, thereby allowing a sufficient distance between the innersurface 1130 of the housing 1100 and the release rod 1530 to accommodatea portion of the electronic circuit system 1900. The engagement surface1534 is disposed at the proximal end portion 1531 of the release rod1530 and is configured to engage a distal end portion 1552 of therelease member 1550, as described below. Although the engagement surface1534 is shown as forming a substantially closed wall the circumscribesthe proximal end portion 1531 of the release rod 1530, in otherembodiments, the release rod 1530 can include an engagement surface 1534having any suitable configuration.

As shown in FIGS. 27 and 32, the release member 1550 of the systemactuator assembly 1500 has a proximal end portion 1551 and a distal endportion 1552, and is movably disposed within the gas cavity 1132. Theproximal end portion 1551 of the release member 1550 includes a flange1553, a sealing member 1560, and a puncturer 1570. As shown in FIG. 32,the spring 1565 of the system actuator assembly 1500 is disposed betweenthe flange 1553 and the distal wall 1133 of the housing 1100 thatdefines a portion of the gas cavity 1132. In this manner, the spring1565 can be transitioned from a first configuration with a relativelyhigh potential energy (e.g., a compressed configuration) to a secondconfiguration with a relatively low potential energy (e.g., anon-compressed configuration) to exert a force on the flange 1553 of therelease member 1550 sufficient to move the release member 1550 withinthe gas cavity 1132, as described in further detail herein.

In this embodiment, the sealing member 1560 substantially circumscribesthe flange 1553 of the release member 1550. In other embodiments, thesealing member 1560 can be any suitable configuration such as, forexample, an over-mold about the flange 1553 of the release member 1550.The sealing member 1560 is configured to be in contact with a portion ofthe inner surface 1130 of the housing 1100 defining the gas cavity 1132such that a portion of the gas cavity 1132 proximal to the flange 1553is substantially fluidically isolated from a portion of the gas cavity1132 distal to the flange 1553. In this manner, when gas is releasedfrom the gas container 1580, the gas is contained in the portion of thegas cavity 1132 proximal to the flange 1553, as described in furtherdetail herein.

The puncturer 1570 disposed at or near the proximal end portion 1551 ofthe release member 1550 is configured to contact and puncture, forexample, a frangible seal of the gas container 1580 when the releasemember 1550 moves proximally within the gas cavity 1151, as described infurther detail herein. As shown in FIG. 32, the length of the gascontainer retention member 1163 of the proximal cap 1160 and the lengthof the release member 1550 collectively determine a distance between thepuncturer 1570 and the frangible seal (not shown) when the medicalinjector 1000 is in the storage configuration (or first configuration).This distance, which is the distance through which the puncturer 1570travels when the medical injector 1000 is actuated, can be adjusted bychanging the length of the gas container 1580, a length and/orarrangement of the gas container retention members 1163 of the proximalcap 1160, and/or the length of the release member 1550. In someembodiments, the actuation time and/or the force exerted by thepuncturer 1570 on the frangible seal can be adjusted by changing thedistance between the puncturer 1570 and the frangible seal.

The distal end portion 1552 of the release member 1550 includes a firstextension 1554 and a second extension 1556. The extensions 1554 and 1556each have projections 1555 and 1557, respectively. As shown in FIGS. 32and 33, the projection 1555 of the first extension 1554 and theprojection 1557 of the second extension 1556 each include a surfaceconfigured to selectively engage the distal wall 1133 of the gas cavity1132. More specifically, the release member 1550 is disposed within thegas cavity 1132 of the housing 1100 such that a portion of eachextension 1554 and 1556 extends through the opening 1134 defined by thedistal wall 1133 prior to actuation of the medical injection 1000. Thus,the surface of each projection 1555 and 1557 engages a distal surface ofthe distal wall 1133 and each are maintained in contact therewith untilactuation of the medical injector 1000. In other words, the projections1555 and 1557 engage the distal wall 1133 to limit proximal movement ofthe release member 1550 prior to actuation of the medical injector 1000.Furthermore, as shown in FIG. 33, an opening 1558 is defined between theextensions 1554 and 1556 (i.e., the first extension 1554 is spaced aparta distance from the second extension 1556). As described in furtherdetail herein, the medical injector 1000 can be actuated to move therelease rod 1530 in the proximal direction such that the engagementsurface 1534 of the release rod 1530 contacts the protrusions 1555 and1557, thereby reducing the distance defined between the extensions 1554and 1556 (i.e., reduces the size of the opening 1558) to an extent thatthe projections 1555 and 1557 can pass through the opening 1134 definedby the distal wall 1133. As such, the spring 1565 can exert a force tomove the release member 1550 in a proximal direction within the gascavity 1132 to cause the puncture member 1570 to puncture the frangibleseal of the gas container 1580, as described in further detail herein.

As shown in FIGS. 34-39, the medicament container assembly 1200 includesa medicament container 1210, the needle 1240, the carrier 1260, and theneedle sheath 1280. The medicament container assembly 1200 functionscooperatively with the mixing actuator rod 1290 and the bias member1295, as described herein. As shown in FIGS. 25 and 27, the mixingactuator rod 1290 includes the proximal end portion 1291 and the distalend portion 1292. The proximal end portion 1291 of the mixing actuatorrod 1290 is disposed in and/or otherwise coupled to the mixing rodrecess 1164 defined by the proximal cap 1160 of the housing 1100. Thedistal end portion 1292 of the mixing actuator rod 1290 includes theflange 1293 and forms a distal surface 1294. The flange 1293 is disposedin the recess 1151 defined by the lock portion 1150 of the housing 1100.The distal surface 1294 of the mixing actuator rod 1290 is disposedwithin the lock portion 1150 of the housing 1100 substantially oppositethe basket 1152 of the lock portion 1150. As shown, for example, inFIGS. 25 and 26, the distal surface 1294 can be concave and/or can besubstantially conical with a diameter that decreases as the distalsurface 1294 extends in the proximal direction. As described in furtherdetail herein, the distal surface 1294 of the mixing actuator rod 1290,the lock portion 1150 of the housing 1100, and the lock portion 1705 ofthe safety lock 1700 collectively define and/or circumscribe a volumeconfigured to receive the lock member 1730 (see e.g., FIGS. 25 and 26).

The medicament container 1210 includes a proximal end portion 1211, adistal end portion 1212, and defines an inner volume 1213 and a bypass1214. The bypass 1214 can be a singular channel bypass or can definemultiple channels. Although the bypass 1214 is shown in FIGS. 34 and 36as an external bypass, in other embodiments, the bypass 1214 can beinternal to the medicament container and/or a part of an elastomericmember disposed in the inner volume 1213. Said another way, in someembodiments a bypass can be configured such that the outer diameter ofthe medicament container 1210 is substantially constant. The bypass 1214is configured to facilitate the mixing and/or injection of a medicamentcontained within the medicament container 1210, as described in furtherdetail herein. In particular, the bypass 1214 is configured to placevarious volumes within the medicament container 1210 in fluidcommunication with each other.

As shown in FIGS. 34 and 36, the distal end portion 1212 of themedicament container 1210 includes a neck 1215 and a distal cap 1216including a seal member 1217. The distal end portion 1212 is configuredto be at least partially disposed within a container-mounting portion1265 of the carrier 1260, as described below. The distal cap 1216 canbe, for example, a crimp seal or cap disposed about the distal endportion 1212 of the medicament container 1210. The seal member 1217 canbe any suitable member, such as, for example, a septum, a valve, afrangible seal, and/or the like. In this manner, the seal member 1217 isconfigured to engage a surface of the medicament container 1210 and aninner surface of the distal cap 1216 to define a fluidic seal, asdescribed in further detail herein.

As described above, the proximal end portion 1211 of the medicamentcontainer 1210 is coupled to and/or otherwise includes the flange 1230.The flange 1230 includes the seal member 1235 (i.e., the outer seal)configured to form a substantially fluid tight seal with a portion ofthe inner surface 1130 of the housing 1100 that defines at least aportion of the medicament cavity 1141. The flange 1230 also includes theseal member 1236 (i.e., the inner seal) that forms a substantially fluidtight seal with an inner portion of the flange 1230 that defines atleast a portion of the medicament cavity 1141.

The proximal end portion 1211 of the medicament container 1210 allowsthe inner volume 1213 to receive a first elastomeric member 1220 and asecond elastomeric member 1221. In some embodiments, the firstelastomeric member 1220 and the second elastomeric member 1221 areplaced within the medicament container 1210 during a fill/finish processto define a diluent volume 1226 and a dry medicament volume 1227 (see,e.g., FIG. 36). Said another way, the diluent volume 1226 is a volumedisposed within the medicament container 1210 defined between the firstelastomeric member 1220 and the second elastomeric member 1221. The drymedicament volume 1227 is a volume disposed within medicament container1210 defined between the second elastomeric member 1220 and the sealmember 1217 disposed at the distal end portion 1213 of the medicamentcontainer 1210. As shown in FIG. 36, the diluent volume 1226 and the drymedicament volume 1227 are defined by the positions of the firstelastomeric member 1220 and the second elastomeric member 1221 relativeto and/or within the medicament container 1210. In some embodiments, thediluent volume 1226 can contain a medicament diluent, such as, forexample, water. In some embodiments, the dry medicament volume 1227 cancontain a lyophilized medicament (e.g., any suitable medicament producedvia any suitable lyophilizing process) including any of the formulationsand/or compositions described herein.

As shown in FIGS. 25 and 27, the proximal end portion 1211 of themedicament container 1210 is coupled to and/or receives a portion of themixing protrusion 1162 of the proximal cap 1160. As described in furtherdetail herein, the medicament container 1210 can be moved within thehousing 1100 and relative to the mixing protrusion 1162, which in turn,can result in movement of the first elastomeric member 1220 and/or thesecond elastomeric member 1221 within the medicament container 1210.While the mixing protrusion 1162 is shown in FIG. 25 as being in contactwith first elastomeric member 1220 prior to actuating the medicalinjector 1000 (e.g., when the medical injector 1000 is in a storage, orfirst, configuration), in other embodiments, the mixing protrusion 1162can be spaced apart from the first elastomeric member 1220 when themedical injector 1000 is in the storage configuration.

The medicament container 1210 can have any suitable size (e.g., lengthand/or diameter). In some embodiments, the medicament container 1210and/or the mixing protrusion 1162 of the proximal cap 1160 can beconfigured (collectively or independently) such that the medicamentcontainer 1210 travels a desired distance during a mixing event (i.e., a“mixing stroke”). In this manner, the medicament container 1210, thediluent contained within the diluent volume 1226, the lyophilizedmedicament contained within the dry medicament volume 1227, and themixing protrusion 1162 can be collectively configured to provide adesired fill volume and delivery volume. Moreover, the length of themedicament container 1210 and the length of the mixing protrusion 1162can be configured such that the medicament container assembly 1200 canfit in the same housing 1100 regardless of the fill volume, the deliveryvolume, and/or the ratio of the fill volume to the delivery volume. Inthis manner, the same housing 1100 and production tooling can be used toproduce devices having various dosages of the medicament. For example,in a first embodiment (e.g., having a fill volume to delivery volumeratio of 0.4), a medicament container has a first length and a mixingprotrusion has a first length. In a second embodiment (e.g., having afill volume to delivery volume ratio of 0.6), a medicament container hasa second length shorter than the first length, and a mixing protrusionhas a second length longer than the first length. In this manner, themixing stroke of the device of the second embodiment is longer than thatof the device of the first embodiment, thereby allowing mixing of agreater dosage. The medicament container of the device of the secondembodiment, however, is shorter than the medicament container of thedevice of the first embodiment, thereby allowing the components of bothembodiments to be disposed within the same housing and/or a housinghaving the same length.

The first elastomeric member 1220 and the second elastomeric member 1221can be of any design or formulation suitable for contact with themedicament (e.g., the diluent contained in the diluent volume 1226and/or a lyophilized medicament contained in the dry medicament volume1227). For example, the elastomeric members 1220 and 1221 can beformulated to minimize any reduction in the efficacy of the medicamentthat may result from contact (either direct or indirect) between theelastomeric members 1220 and 1221 and the medicament. In someembodiments, the elastomeric members 1220 and 1221 can be made fromand/or can include butyl rubber, such as chlorobutyl rubber, bromobutylrubber, and/or the like. In some embodiments, the first elastomericmember 1220 and the second elastomeric member 1221 can be formulated tominimize any leaching or out-gassing of compositions that may have anundesired effect on the medicament. In other embodiments, theelastomeric members 1220 and 1221 can be formulated to maintain itschemical stability, flexibility and/or sealing properties when incontact (either direct or indirect) with the medicament over a longperiod of time (e.g., for up to six months, one year, two years, fiveyears or longer).

As described above, the medicament container 1210 is configured toengage and/or be coupled to the carrier 1260 (see e.g., FIGS. 25, 27 and37-39). Referring to FIGS. 37-39, the carrier 1260 includes the mixingportion 1261, the container-mounting portion 1265, the lock portion1275, the needle 1240, and the needle sheath 1280. The mixing portion1261 extends from the container-mounting portion 1265 and the lockportion 1275. As shown in FIG. 37, the mixing portion 1261 includes aproximal flange 1262 that defines an opening 1263. The opening 1263 isconfigured to receive a portion of the mixing actuator rod 1290. Thearrangement of the opening 1263 is such that the proximal flange 1262 ismovably disposed about the mixing actuator rod 1290 (i.e., the proximalflange 1262 and the carrier 1260 can slide about the actuator rod 1290).Moreover, as shown in FIG. 25, the arrangement of the medicamentcontainer assembly 1200 is such that the bias member 1295 is disposedabout the mixing actuator rod 1290 and between the flange 1293 at thedistal end portion 1292 of the mixing rod actuator 1290 and the proximalflange 1262 of the carrier 1260. In this manner, the medical injector1000 can be actuated to transition the bias member 1295 from a firstconfiguration with a relatively high potential energy (e.g., acompressed configuration) to a second configuration with a relativelylow potential energy (e.g., a non-compressed configuration) to exert aforce on the proximal flange 1262 of the mixing portion 1261 of thecarrier 1260 sufficient to move the carrier 1260 within the mixingactuator cavity 1142 in the proximal direction, as described in furtherdetail herein.

The container-mounting portion 1265 of the carrier 1260 includes and/orforms a substantially annular wall within which a portion of themedicament container 1210 is disposed. More specifically, thecontainer-mounting portion 1265 includes an inner surface 1266 with afirst portion 1267 and a second portion 1268 (see e.g., FIG. 39). Inthis embodiment, the first portion 1267 of the inner surface 1266 has adiameter that is greater than a diameter of the second portion 1268. Thediameter of the first portion 1267 and the diameter of the secondportion 1268 can each be associated with a diameter of a differentportion of the medicament container 1210, thereby allowing themedicament container 1210 to selectively engage the container-mountingportion 1265 in various positions during the various stages of operationof the medical injector 1000. As shown in FIG. 39, the first portion1267 of the inner surface 1266 includes a first shoulder 1270.Similarly, the inner surface 1266 includes a second shoulder 1271disposed at or near a transition from the first portion 1267 to thesecond portion 1268. In this manner, the container-mounting portion 1265of the carrier 1260 can selectively engage a corresponding portion ofthe medicament container 1210 to at least temporarily maintain themedicament container 1210 in a fixed position relative to the carrier1260, as described in further detail herein. Furthermore thecontainer-mounting portion 1265 includes a needle mount 1272 configuredto couple the needle 1240 to the carrier 1260 such that a proximal endportion 1241 of the needle 1240 is disposed within a volumecircumscribed by the second portion 1268 of the inner surface 1266 (seee.g., FIG. 39).

As shown in FIG. 37, the lock portion 1275 of the carrier 1260 includesa first member 1276 having a tab 1277, and a second member 1278 having atab 1279. The lock portion 1275 is configured such that a space isdefined between the first member 1276 and the second member 1278. Asdescribed above, the carrier 1260 can be disposed in the medicamentcavity 1241 such that the tabs 1277 and 1279 are disposed in thecorresponding carrier lock apertures 1113 defined by the housing 1100.In some embodiments, the arrangement of the lock portion 1275 can besuch that the tabs 1277 and 1279 engage a surface of the housing 1100defining the carrier lock apertures 1113 (e.g., a proximal surface). Inthis manner, the lock portion 1275 limits a proximal movement of thecarrier 1260 prior to actuating the medical injector 1000.

As shown in FIGS. 37 and 39, the needle 1240 includes the proximal endportion 1241 and a distal end portion 1242. In this embodiment, theproximal end portion 1241 and the distal end portion 1242 are eachsharpened (or beveled). In other embodiments, the proximal end portion1241 and/or the distal end portion 1242 need not be sharpened. Theneedle 1240 is coupled to the carrier 1260 such that the proximal endportion 1241 of the needle 1240 is at least partially disposed withinthe volume circumscribed by the second portion 1268 of the inner surface1266. At least a portion of the needle 1240 is configured to be disposedwithin the needle sheath 1280 prior to actuating the medical injector1000. The needle sheath 1280 includes a proximal end portion 1281, adistal end portion 1282, and a rib 1285. The needle sheath 1280 alsodefines a bore 1283 within which a needle plug 1284 is disposed at ornear the distal end portion 1282 of the needle sheath 1280. As shown inFIG. 39, the needle sheath 1280 is at least temporarily disposed about aportion of the needle mount 1272 to define a friction fit, a snap fit,and/or the like. Thus, the needle sheath 1280 can be coupled to thecarrier 1260 and about the needle 1240 until a force is exerted that issufficient to remove the needle sheath 1280 from the carrier 1260. Theneedle plug 1824 can be any suitable material such as a cork material orany other suitable porous material (e.g., any suitable Porex™ material)to allow for exposure to ethylene oxide during a sterilizationoperation. As such, the needle sheath 1280 can be disposed about theneedle 1240 prior to use of the medical injector 1000 to substantiallymaintain the sterility of the needle 1240 and to prevent inadvertentcontact with the sharpened distal end 1241 thereof.

While the needle 1240 is shown and described above as being coupled tothe carrier 1260, in other embodiments, the needle 1240 can bemonolithically formed with the carrier 1260. Similarly, in someembodiments, the needle 1240 can be coupled to or monolithically formedwith the medicament container 1210. Thus, during manufacturing and/orassembly the needle 1240 and the carrier 1260 and/or the medicamentcontainer 1210, as well as the needle sheath 1280 disposed about aportion of the needle 1280, can be maintained in an aseptic environment,which in some instances, can obviate a need for further sterilizationsuch as, for example, ethylene oxide.

FIGS. 40-46 illustrate the electronic circuit system 1900 included inthe medical injector 1000. The electronic circuit system 1900 includes aprinted circuit board 1920, a battery assembly 1935, an audio outputdevice 1930, three light emitting diodes (LEDs) 1940, a battery clip1910 (see e.g., FIG. 50), a first switch 1925, and a second switch 1926.The electronic circuit system 1900 is disposed within the housing 1100(see e.g., FIG. 50) and is configured to output an electronic outputassociated with the use of the medical injector 1000.

In some embodiments, the electronic circuit system 1900 can be coupledto the housing 1100 by any suitable means such as an adhesive, a clip, alabel, and/or the like. For example, the electronic circuit system 1900includes a batter clip 1910 coupled to the housing 1100. As described inmore detail herein, the battery clip protrusion 1136 (see FIG. 50) ofthe housing 1100 is configured to hold the battery clip 1910 in place.Similarly stated, the battery clip protrusion 1136 of the housing 1100is configured to exert a force on the battery clip 1910 to ensure thatelectrical contact between the battery assembly 1935 and the batteryclip 1910 is maintained when the battery isolation protrusion 1185 ofthe cover 1180 is removed, as described in further detail herein.

As shown and described above with respect to FIG. 16, the housing 1100defines the sounds apertures 1108, the LED aperture 1115, the systemactivation opening 1124, and the electronic activation opening 1125. Theelectronic circuit system 1900 is disposed in the housing 1100 such thata front face of the audio output device 1930 is disposed adjacent thesound apertures 1108. In this manner, the sound apertures 1108 areconfigured to allow sound produced by the audio output device 1930 topass from the audio output device 1930 to a region outside of thehousing 1100.

The printed circuit board 1920 of the electronic circuit system 1900includes a substrate 1921, the first switch 1925, and the second switch1926. In addition, the printed circuit board 1920 defines a notch 1922(see e.g., FIGS. 40 and 41). Although not specifically shown herein, thesubstrate 1921 of the printed circuit board 1920 includes and/or isotherwise coupled to any suitable electrical components for theelectronic circuit system 1900 to operate as desired. For example, theelectrical components can be one or more resistors, capacitors,inductors, switches, accelerometers, microcontrollers, microprocessorsand/or the like. The printed circuit board 1920 may also be constructedof materials other than a flexible substrate, such as a FR4 standardboard (rigid circuit board).

As shown in FIGS. 43-46, the first switch 1925 is disposed on thesubstrate 1921 such that a portion of the first switch 1925 extends intothe notch 1922 defined by the printed circuit board 1920. Similarly, thesecond switch 1926 is disposed on the substrate 1921 such that a portionof the second switch 1926 extends beyond a boundary (e.g., an edge orcontour) of the printed circuit board 1920. In this manner, the firstswitch 1925 and the second switch 1926 can be actuated, activated,and/or otherwise engaged to transition between a first configuration,associated with a first electrical state, and a second configuration,associated with a second electrical state. In some embodiments, thefirst switch 1925 and the second switch 1926 can be a reversibleelectromechanical switch and/or a reversible optical switch. In otherembodiments, the first switch 1925 and the second switch 1926 can be anengagement or frangible portion of an electrical circuit. In suchembodiments, the first switch 1925 and the second switch 1926 can be,for example, an irreversible switch of the types shown and described inU.S. Pat. No. 7,731,686, entitled “Devices, Systems and Methods forMedicament Delivery,” filed Jan. 9, 2007, which is incorporated hereinby reference in its entirety. In this embodiment, the first switch 1925and the second switch 1926 are reversible electromechanical switchesthat can be manipulated to open or close an electrical circuit. In otherembodiments, a button, toggle, dial, switch, and/or other mechanism maybe used to transition the electronic circuit system 1900 between an onor off state.

Specifically, as shown in FIG. 44, the safety lock (or mixing actuator)1700 includes the electronic activation protrusion 1720 that is at leastpartially disposed in the notch 1922 defined by the printed circuitboard 1920 when the safety lock 1700 is coupled to the housing 1100(e.g., when the medical injector 1000 is in a storage configurationand/or prior to use). With the electronic activation protrusion 1720disposed in the notch 1922, the first switch 1925 is in a firstconfiguration. That is to say, the electronic activation protrusion 1720can engage the portion of the first switch 1925 that is disposed in thenotch 1922 (described above) to place and/or maintain the first switch1925 in its first configuration. In use, the safety lock 1700 can bemanipulated and removed from the housing 1100, thereby initiating themixing operation and enabling actuation of the device 1000. Movement ofthe safety lock 1700 also moves the electronic activation protrusion1720 relative to the electronic circuit system 1900. As indicated by thearrow AA in FIG. 45, the movement of the safety lock 1700 moves theelectronic activation protrusion 1720 out of the notch 1922 defined bythe printed circuit board 1920 and thus, out of engagement with thefirst switch 1925. Thus, with the electronic activation protrusion 1720out of engagement with the first switch 1925, the first switch 1925 cantransition to its second configuration, as shown in FIG. 45 (e.g., thefirst switch 1925 can be biased or the like to transition to its secondconfiguration).

In a similar manner, the second switch 1926 can be engaged by theelectronic activation protrusion 1520 (see, e.g., FIG. 29) of the base1510. For example, as shown in FIGS. 44 and 45, the base 1510 can bedisposed in its first position relative to the housing 1100 (e.g., theretention members 1519 of the base 1510 are disposed in and/or otherwisein contact with the distal actuator retention notches 1112) such thatthe electronic activation protrusion 1520 of the base 1510 is disposedin a distal position relative to the second switch 1926. That is to say,the electronic activation protrusion 1520 is not in contact with and/orotherwise does not engage the second switch 1926 when the base 1510 isin its first position relative to the housing 1100. In use, once thesafety lock 1700 has been removed from the housing 1100, the base 1510can be moved toward its second position relative to the housing 1100, asindicated by the arrow BB in FIG. 46. As described below, movement ofthe base 1510 actuates the system actuator assembly 1500. The movementof the base 1510 also moves the electronic activation protrusion 1520 ofthe base 1510 in, for example, the proximal direction and into contactand/or engagement with the second switch 1926. Thus, the electronicactivation protrusion 1520 of the base 1510 transitions the secondswitch 1926 from its first configuration to its second configuration, asshown in FIG. 46. Thus, the first switch 1925 and the second switch 1926can be actuated and/or activated to transition between a first electricstate and a second electric state, which in turn, can cause theelectronic circuit system 1900 to perform one or more electronicoperations, as described in further detail herein.

The battery clip 1910 (shown in FIG. 50) includes an attachment portion1912 and a contact portion 1913. The attachment portion 1912 receives ascrew 1911 to couple the battery clip 1910 to the battery clipprotrusion 1136 of the housing 1100. In this manner, the battery clipprotrusion 1136 maintains the position of the battery clip 1910 withrespect to the printed circuit board 1920. The contact portion 1913 ofthe battery clip 1910 is configured to selectively contact a surface ofthe battery assembly 1935 when the cover 1180 is removed from thehousing 1100, as described below. Note that FIG. 50 shows the injector1000 in the first (or initial) configuration, in which the batteryisolation protrusion 1185 is disposed between the contact portion 1913of the battery clip 1910 and the second surface of the battery assembly1935.

The battery assembly 1935 of the electronic circuit system 1900 includestwo batteries stacked on top of one another. In other embodiments, theelectronic circuit system can include any number of batteries and/or anysuitable type of power source. In some embodiments, for example, thebattery assembly can include Lithium batteries such as, for example,CR11616, CR12016s, type AAA or the like. The battery assembly 1935 has afirst surface that can contact, for example, an electrical contact (notshown) disposed on the printed circuit board 1920, and a second surfacethat can selectively contact, for example, the contact portion 1913 ofthe battery clip 1910 (see e.g., FIG. 50). More particularly, when thecover 1180 is coupled to the housing 1100, a portion of the batteryisolation protrusion 1185 is disposed between the contact portion 1913of the battery clip 1910 and the second surface of the battery assembly1935, thereby maintaining electric isolation therebetween. When thecover 1180 is removed from the housing 1100, the battery isolationprotrusion 1185 is likewise removed from the housing 1100 and thecontact portion 1913 of the battery clip 1910 is placed in contact withthe second surface of the battery assembly 1935 (e.g., the battery clip1910 is biased or the like to place the contact portion 1913 in contactwith the battery assembly 1935). When both the electrical contact of thesubstrate 1921 and the contact portion 1913 of the battery clip 1910contact the battery assembly 1935, the batteries of the battery assembly1935 are placed in electrical communication with the electronic circuitsystem 1900. Said another way, when the electrical contact of thesubstrate 1921 and the contact portion 1913 of the battery clip 1910contact the battery assembly 1935, the battery assembly 1935 isconfigured to supply power to the electronic circuit system 1900.

The audio output device 1930 of the electronic circuit system 1900 isconfigured to output audible sound to a user in response to use of themedical injector 1000. In some embodiments, the audible output device1930 can be a speaker. In some embodiments, the audible sound can be,for example, associated with a recorded message and/or a recordedspeech. In other embodiments, the audible instructions can be an audiblebeep, buzzer, a series of tones and/or or the like. Moreover, when theelectrical contact on the printed circuit board 1920 and the contactportion 1913 of the battery clip 1910 are in contact with the batteryassembly 1935, the battery assembly 1935 can supply electrical power tothe electronic circuit system 1900, which is operable in causing theaudio output device 1930 to output audible sound.

Although not shown, in some embodiments, the electronic circuit system1900 can have a network interface device configured to operativelyconnect the electronic circuit system 1900 to a remote device (notshown) and/or a communications network (not shown). In this manner, theelectronic circuit system 1900 can send information to and/or receiveinformation from the remote device. The remote device can be, forexample, a remote communications network, a computer, acompliance-monitoring device, a cell phone, a personal digital assistant(PDA), and/or the like. Such an arrangement can be used, for example, todownload replacement processor-readable code from a central network tothe electronic circuit system 1900. In some embodiments, for example,the electronic circuit system 1900 can download information associatedwith a medical injector 1000, such as an expiration date, a recallnotice, updated use instructions or the like. Similarly, in someembodiments, the electronic circuit system 1900 can upload complianceinformation associated with the use of the medical injector 1000 via thenetwork interface device.

Although not shown, in some embodiments, the electronic circuit system1900 can include a radio (also referred to as a receiver, transmitterand/or transceiver) operable to send signals to, and/or receive radiosignals, such as Bluetooth®, ZigBee, WiFi, cellular telephone signals,etc. For example, in some embodiments, the electronic circuit system1900 includes components of and/or operates in accordance with themethods described in U.S. Patent Publication No. 2014/0243749, entitled“Devices, Systems and Methods for Locating and Interacting withMedicament Delivery Systems,” filed Dec. 27, 2013, which is incorporatedherein by reference in its entirety. For example, in some embodiments,the electronic circuit system can include a Bluetooth® processor havingan integral radio. In other embodiments, the radio can include aprocessor distinct from the “primary” processor.

Although not shown, in some embodiments, the electronic circuit system1900 can include an orientation sensor, an accelerometer, an opticalsensor, and/or any other suitable “shake” sensor. Similarly stated, theelectronic circuit system 1900 can include a sensor that can determinephysical differences before and after user actions (e.g., such asshaking, rotating, or the like). In this manner, the electronic circuitsystem 1900 can produce one or more outputs associated with theorientation of the medical injector 1000 during use. For example, insome embodiments, the electronic circuit system 1900 can produce analarm (beep or buzzer) or other output to indicate when the needle isoutside of a predetermined “vertical” range. Specifically, during themixing process, it is advantageous for the needle 1240 to be pointedupwards within a predetermined angular range of vertical. Similarlystated, it is advantageous for a longitudinal axis of the needle 1240 tobe parallel and/or aligned with a vertical axis (or within apredetermined angular range of the vertical axis). In this manner,distal end portion 1242 of the needle 1240 will be pointed upwardsduring the mixing process to allow any air trapped within the medicamentcontainer 1210 to escape via the needle 1240 (e.g., a priming step). Byproducing an output via the electronic circuit system 1900, the medicalinjector 1000 can alert the user that the orientation of the device isnot suitable for initiation of the mixing operation.

In some embodiments, the orientation sensor can sense if the medicalinjector 1000 has been placed in contact with a patient in a desiredorientation, position and/or manner. In this arrangement, other sensorscan be used along with the orientation sensor and/or accelerometer inorder to determine relative position and/or orientation of the medicalinjector 1000. For example, in some embodiments, the medical injector1000 can be configured to expose a relatively small portion of theneedle 1240 during subcutaneous injection. Thus, the orientation sensorand/or any other sensor can be used to sense when the medical injector1000 is substantially perpendicular to an injection surface (i.e.,approximately 90 degrees to a tangent line of the injection surface) ofthe patient to allow for proper insertion of the exposed portion of theneedle 1240. In addition to sensing the orientation and/or position ofthe medical injector 1000, the orientation sensor and/or any othersensor included in the electronic circuit system 1900 can be configuredto send a signal, for example, to a processor, which in turn, can causean audible output (e.g., via the audio device 1930), a visual output(e.g., via the LEDs 1940), and/or any other suitable electronic output(e.g., a haptic output and/or the like) to alert the user if the medicalinjector 1000 is not disposed in a proper position and/or orientationduring a given phase of an injection event.

In other embodiments, the electronic circuit system 1900 can produce anindication associated with rapid movement or shaking of the injectiondevice 1000. For example, in some embodiments, the electronic circuitsystem 1900 can produce an audible instruction for the user to shake thedevice for five seconds after removing the safety lock (or mixingactuator) 1700. The accelerometer can then sense the rapid motion orshaking of the injection device 1000, and produce a countdown timerstarting when the shaking motion is first detected (i.e., exceeds apredetermined threshold), and continuing while the shaking motioncontinues. In some embodiments, the electronic circuit system 1900 canstop the countdown timer if the shaking motion stops or otherwise dropsbelow a predetermined threshold. In this manner, the user is prompted tocontinue the shaking (rather than having the countdown timer beingsimply a “timed script”).

In yet other embodiments, the electronic circuit system 1900 can includea sensor (e.g., an optical sensor) that can produce a signal associatedwith the status of mixing. For example, the sensor can detect solidparticles (e.g., portions of the lyophilized medicament) indicating thatthe dry medicament has not yet been fully mixed. In response to thesignal, the electronic circuit system can produce a light, an audibleoutput, or the like, instructing the user to continue shaking thedevice.

FIGS. 47-50 show the cover 1180 of the medical injector 1000. The cover1180 can be any suitable configuration and can include any suitablefeature to house, contain and/or protect portions of the medicalinjector 1000. The cover 1180 includes a proximal end portion 1181 and adistal end portion 1182, and defines a cavity 1184 and a set of statuswindows 1183. The cavity 1184 of the cover 1180 is configured to receiveat least a portion of the housing 1100. The status windows 1183 aredisposed on opposite sides of the cover 1180 and are configured suchthat, when the portion of the housing 1100 is disposed within the cover1180, the status windows 1183 of the cover 1180 are at least partiallyaligned with the corresponding status indicator aperture 1107 of thehousing 1100. Thus, a user can visually inspect a portion of themedicament container assembly 1200 via the status windows 1183 of thecover 1180 and the status indicator apertures 1107 of the housing 1100.As described above, the electronic circuit system 1900 can be actuatedonly when the housing 1100 is at least partially removed from the cover1180. Thus, the cover 1180 also functions as a safety lock to limitmedicament delivery.

As shown in FIG. 48, the distal end portion 1182 of the cover 1180includes the battery isolation protrusion 1185 disposed in the cavity1184. As described above, the battery isolation protrusion 1185 isconfigured to be removably disposed between the second surface of thebattery assembly 1935 and the contact portion 1913 of the battery clip1910 (see e.g., FIG. 50).

FIGS. 51-54 show the safety lock (or mixing actuator) 1700 of themedical injector 1000. The safety lock 1700 of the medical injector 1000includes a proximal end portion 1701, a distal end portion 1702, and aninner surface 1704 that defines an inner volume 1707. The safety lock1700 defines a lock portion opening 1709, a needle sheath aperture 1725and a battery isolation protrusion aperture 1721. The lock portionopening 1709 is configured to receive, at least in part, the lockportion 1150 of the housing 1100, as described in further detail herein.The needle sheath aperture 1725 is configured to receive a portion ofthe needle sheath 1280. The battery isolation protrusion aperture 1721is configured to receive the battery isolation protrusion 1185 of thecover 1180. As such, the battery isolation protrusion 1185 can extendthrough the battery isolation protrusion aperture 1721 of the safetylock 1700, the battery isolation protrusion opening 1516 of the base1510, and the system activation opening 1124 to be partially disposedwithin the housing 1100 and/or in engagement with the electronic circuitsystem 1900, as described above. Similarly stated, the battery isolationprotrusion aperture 1721 of the safety lock 1700 is aligned with thesystem activation opening 1124 of the housing 1100, such that thebattery isolation protrusion 1185 can be disposed within the housing1100 when the cover 1180 is disposed about a portion of the housing1100.

The inner surface 1704 of the safety lock 1700 includes the lock portion1705, the engagement portion 1710, the lock rod 1715, and the electronicactivation protrusion 1720. The lock portion 1705 can be any suitableconfiguration. In this embodiment, the lock portion 1705 of the safetylock 1700 includes a set of lock arms 1706 each of which extend from theinner surface 1704 of the safety lock 1700. More specifically, the lockportion 1705 includes a set of eight lock arms 1706 that are each evenspaced around a perimeter (in this embodiment, a circumference) of thelock portion opening 1709. In other words, the lock arms 1706 are in asymmetrically arrangement and collectively circumscribe the lock portionopening 1709. As shown in FIGS. 53 and 54, each lock arm 1706 includes atab 1708 (e.g., a flange, protrusion, bend, curve, formation, etc.)disposed at a proximal end portion of the lock arm 1706.

Referring back to FIGS. 25 and 26, when the safety lock 1700 is coupledto the housing 1100 (e.g., in a first or locked position), the lockportion 1705 of the safety lock 1700 receives and/or otherwise engagesthe lock portion 1150 of the housing 1100. More particularly, theopenings 1153 defined by the lock portion 1150 of the housing 1100 (seee.g., FIGS. 18-21) receive a corresponding lock arm 1706 included in thelock portion 1705 of the safety lock 1700. In this manner, the lockportion 1150 of the housing 1100, the distal end portion 1292 of themixing actuator rod 1290, and the lock portion 1705 of the safety lock1700 collectively define a interlocked arrangement, which can, forexample, substantially enclose or surround a volume (see e.g., FIGS. 25,26, and 56) configured to receive the lock member 1730. Specifically, inthis embodiment, the lock member 1730 is a ball, bearing, or the like,and is disposed in the collectively formed volume. The arrangement ofthe lock portion 1150 of the housing 1100, the lock portion 1705 of thesafety lock 1700, and at least the distal surface 1294 of the mixingactuator rod 1290 is such that the lock member 1730 selectively locksand/or maintains the safety lock 1700 in a fixed position relative tothe housing 1100 when the medical injector 1000 is in a firstorientation. Specifically, the position of the lock member 1730maintains the safety lock 1700 in a fixed position relative to thehousing 1100 when an angle formed between the distal end portion 1242 ofthe needle 1240 and the upward vertical axis (the “tilt angle”) isgreater than about ±25 degrees, about ±30 degrees, about ±35 degrees,about ±45 degrees, or about ±60 degrees. When the medical injector 1000is in a first orientation, the lock member 1730 is disposed in thebasket 1152 defined by the lock portion 1150 of the housing 1100 (e.g.,in a first position). In this position, the lock member 1730substantially prevents the tab 1708 of at least some of the lock arms1706 from being moved from a proximal position relative to the lockmember 1730. In other words, the lock member 1730 substantially preventsthe safety lock 1700 from being removed from the housing 1100.

Conversely, when the medical injector 1000 is placed in a secondorientation (e.g., oriented such that the tilt angle is less than about±25 degrees, about ±30 degrees, about ±35 degrees, about ±45 degrees, orabout ±60 degrees), the lock member 1730 can be disposed on or adjacentto the distal surface 1294 of the mixing actuator rod 1290 (e.g., in asecond position). In this position, the lock member 1730 is aligned withan opening that is substantially circumscribed by the tabs 1708 of thelock arms 1706. In other words, the lock member 1730 is in a positionthat allows the tabs 1708 of the lock arms 1706 to be moved in thedistal direction relative to the lock member 1730. Thus, when the lockmember 1730 is in the second position (i.e., when the medical injector1000 is in a second orientation), the safety lock 1700 can be removedfrom the housing 1100, as described in further detail herein.

The lock rod 1715 extends from the inner surface 1704 of the safety lock1700 and is disposed in the safety lock rod portion 1515 of the needleopening 1514 defined by the base 1510 and the lock rod opening 1122defined by the housing 1100 when the safety lock 1700 is coupled to thehousing 1100. In this manner, a portion of the lock rod 1715 is disposedin the housing 1100 when the safety lock 1700 is coupled to the housing1100. Moreover, as described above, a portion of the lock rod 1715 is incontact with the lock portion 1275 of the carrier 1260 and/or otherwisedisposed between the first member 1276 and second member 1278 of thelock portion 1275 (see e.g., FIGS. 43 and 56). Accordingly, the lock rod1715 is configured to maintain at least a portion of the tabs 1277 and1279 of the first member 1276 and second member 1278, respectively, inthe corresponding lock aperture 1113 defined by the housing 1100.Therefore, when the safety lock 1700 is coupled to the housing 1100, thelock rod 1715 can engage the carrier 1260 to limit and/or substantiallyprevent proximal movement of the carrier 1260 within the medicamentcavity 1141 of the housing 1100. Accordingly, when the safety lock 1700is coupled to the housing 1100, the mixing operation (which results fromproximal movement of the carrier 1260) cannot be commenced.

The electronic activation protrusion 1720 extends from the inner surface1704 of the safety lock 1700. As described above, the electronicactivation protrusion 1720 is at least partially disposed in the batteryisolation protrusion opening 1516 defined by the base 1510 and thesystem activation opening 1124 defined by the housing 1100 to engage aportion of the electronic circuit system 1900. Specifically, a portionof the electronic activation protrusion 1720 is disposed in the notch1922 defined by the printed circuit board 1920 and in contact and/orengagement with the first switch 1925 when the safety lock is coupled tothe housing 1100, as described above.

The engagement portion 1710 of the safety lock 1700 includes engagementmembers 1711. As shown in FIG. 52, in this embodiment, the engagementportion 1710 includes a pair of engagement members 1711 disposed onopposite sides of the needle sheath aperture 1725 and extending in aproximal direction from the inner surface 1704. The engagement members1711 each have a tab 1712 that extends from a surface of thecorresponding engagement member 1711. The tabs 1712 are configured toengage the rib 1285 disposed at a distal end portion 1282 of the needlesheath 1280 (see, e.g., FIG. 39, which shows the rib 1285). In thismanner, distal movement of the safety tab 1700 results in acorresponding distal movement (e.g., removal of) the needle sheath 1280,as described in further detail herein.

FIGS. 55-65 illustrate the medical injector 1000 in use. As shown inFIGS. 55 and 56, the medical injector 1000 is first enabled by removingthe cover 1180 from the housing 1100, thereby transitioning the medicalinjector 1000 from the first (or initial) configuration to the secondconfiguration, as indicated by the arrow CC in FIG. 55. When the cover1180 is moved in the distal direction (e.g., in the direction of thearrow CC) with respect to the housing 1100, the battery isolationprotrusion 1185 is removed from the area between contact portion 1913 ofthe battery clip 1910 and the second surface of the battery assembly1935. In this manner, the battery assembly 1935 is operatively coupledto the electronic circuit system 1900 when the cover 1180 is removed,thereby providing power to the electronic circuit system 1900. Similarlystated, the electronic circuit system 1900 is actuated when the cover1180 is removed.

When power is provided, as described above, the electronic circuitsystem 1900 can output one or more predetermined electronic outputs. Forexample, in some embodiments, the electronic circuit system 1900 canoutput an electronic signal associated with recorded speech to the audiooutput device 1930. Such an electronic signal can be, for example,associated with a .WAV file that contains a recorded instruction,instructing the user in the operation of the medical injector 1000. Suchan instruction can state, for example, “Remove the safety tab near thebase of the auto-injector to initiate mixing.” The electronic circuitsystem 1900 can simultaneously output an electronic signal to one ormore of the LEDs 1940, thereby causing one or more of the LEDs 1940 toflash a particular color. In this manner, the electronic circuit system1900 can provide both audible and visual instructions to assist the userin the initial operation of the medical injector 1000.

In other embodiments, the electronic circuit system 1900 can output anelectronic output associated with a description and/or status of themedical injector 1000 and/or the medicament contained therein. Forexample, in some embodiments, the electronic circuit system 1900 canoutput an audible message indicating the symptoms for which themedicament should be administered, the expiration date of themedicament, the dosage of the medicament or the like.

In yet other embodiments, the electronic circuit system 1900 can outputa wireless signal to a cell phone, computer, compliance tracking device,emergency dispatch system, and/or the like. For example, in someembodiments, the electronic circuit system 1900 can output an wirelesssignal to a compliance tracking device, which receives the signal andmonitors the activity (e.g., the arming of, the use of or the like) ofthe medical injector 1000.

In some embodiments, the medical injector 1000 can be repeatedly movedbetween the first configuration and the second configuration when thecover 1180 is moved repeatedly between the first position and the secondposition, respectively. Said another way, in some embodiments, the cover1180 can be removed and replaced about the housing 1100 any number oftimes. When the cover 1180 is moved from the second position to thefirst position, the battery isolation protrusion 1185 is reinsertedbetween the contact portion 1913 of the battery clip 1910 and the secondsurface of the battery assembly 1935, deactivating the electroniccircuit system 1900. When the cover 1180 is moved from the firstposition to the second position a second time, the electronic circuitsystem 1900 is once again activated. In other embodiments, the cover1180 is configured to be removed from the housing 1100 only one time andthe electronic circuit system 1900 is therefore configured output asingle electronic output in response thereto. In some such embodiments,the cover 1180 can be configured to remove the needle sheath 1280 andthe electronic circuit system 1900 can warn the user about thecompromised sterility of the needle 1240.

After the cover 1180 is removed from the housing 1100, the medicalinjector 1000 is in the second configuration. As shown in FIG. 56, themedical injector 1000 is in a locked or pre-actuated position while inthe second configuration. Thus, the lock rod 1715 of the safety lock1700 is disposed between the first member 1276 and the second member1278 of the lock portion 1275 of the carrier 1260. As such, the tab 1277of the first member 1276 and the tab 1279 of the second member 1278 areeach maintained in a corresponding carrier lock aperture 1113 defined bythe housing 1100. With the safety lock 1700 coupled to the housing 1100and/or the base 1510, the carrier 1260 is maintained, for example, in adistal position within the medicament cavity 1241. More specifically,the lock rod 1715 exerts a lateral force on the first member 1276 andthe second member 1278, thereby maintaining at least a portion of thetabs 1277 and 1279 within the corresponding carrier lock aperture 1113.In this manner, the tabs 1277 and 1279 can contact a surface of thehousing 1100 defining a proximal portion of the corresponding carrierlock aperture 1113, which in turn, can exert a reaction force sufficientto maintain the bias member 1295 in its first configuration (e.g., acompressed or high potential energy configuration. Therefore, themedicament container assembly 1200 remains in a first configuration(e.g., a pre-mixed configuration). In this configuration, the diluentvolume 1226 is separated and/or fluidically isolated from the drymedicament volume 1227. The proximal end portion 1241 of the needle 1240is disposed distal to the seal member 1217 of the medicament container1210 and is therefore substantially isolated from the medicament.Furthermore, the distal end portion 1242 of the needle 1240 is disposedwithin the needle sheath 1280 such that a user is protected from a sharppoint defined by the distal end 1242 of the needle 1240, and thesterility of the needle 1240 is maintained.

Moreover, as shown in FIG. 56, the medical injector 1000 is orientedsuch that the longitudinal axis of the needle 1240 is aligned withand/or parallel to a vertical axis, but with the distal end portion 1242pointed downward. Thus, a tilt angle formed between the distal endportion 1242 of the needle 1240 and the upward vertical axis is 180degrees. The arrangement of the lock portion 1150 of the housing 1100and the lock portion 1705 of the safety lock 1700 causes the lock member1730 to move within the basket 1152 and into engagement with the lockarms 1706 (see FIGS. 2 and 56). In this manner, when the medicalinjector 1000 is in the second configuration, the safety lock (or mixingactuator) 1700 cannot be moved relative to the housing 1100. Althoughthe medical injector 1000 is shown and described as being in the secondconfiguration when the tilt angle is 180 degrees, in other embodiments,the medical injector 1000 can be maintained in the second configurationwhen the tilt angle is between about 90 degrees and about 270 degrees(i.e., is greater than about ±90 degrees), between about 75 degrees andabout 285 degrees (i.e., is greater than about ±75 degrees), betweenabout 60 degrees and about 300 degrees (i.e., is greater than about ±60degrees), between about 45 degrees and about 315 degrees (i.e., isgreater than about ±45 degrees), between about 35 degrees and about 325degrees (i.e., is greater than about ±35 degrees), between about 30degrees and about 330 degrees (i.e., is greater than about ±30 degrees),and between about 25 degrees and about 335 degrees (i.e., is greaterthan about ±25 degrees), between about 20 degrees and about 340 degrees(i.e., is greater than about ±20 degrees), between about 15 degrees andabout 345 degrees (i.e., is greater than about ±15 degrees), betweenabout 10 degrees and about 350 degrees (i.e., is greater than about ±10degrees), and between about 5 degrees and about 355 degrees (i.e., isgreater than about ±5 degrees). The medical injector 1000 can be movedfrom the second configuration to a third configuration by reorientingthe medical injector 1000 from the first orientation, in which the base1510 is substantially distal to the housing 1100 (e.g., FIGS. 45 and 46,or otherwise oriented such that the tilt angle is greater than apredetermined value) to a second orientation, in which the base 1510 issubstantially proximal to the housing 1100 (e.g., with the needlepointed “upwards” as shown in FIGS. 57 and 58, or otherwise orientedsuch that the tilt angle is less than a predetermined value). Similarlystated, the medical injector 1000 can be moved from the secondconfiguration to a third configuration by first reorienting the medicalinjector 1000 to a second orientation in which the tilt angle is within(or less than) any of the ranges set forth herein, such as, for example,less than about 30 degrees from the upward vertical orientation (i.e.,between about 330 and 30 degrees, or said another way, within about 30degrees of the vertical axis in an upward direction).

With the medical injector 1000 in the second orientation, the medicalinjector 1000 can be manipulated by removing the safety lock 1700 fromthe housing 1100, as indicated by the arrow DD in FIG. 57. Morespecifically, as described above, prior to actuation of the medicalinjector 1000 and when the medical injector 1000 is in the firstorientation, the lock member 1730 is disposed in the basket 1152 definedby the lock portion 1150 of the housing 1100. Thus, the lock member 1730substantially prevents the removal of the safety lock 1700. As shown inFIG. 58, when the medical injector 1000 is moved to its secondorientation, the lock member 1730 moves (e.g., under the force ofgravity) to a position adjacent to and/or otherwise in contact with thetapered distal surface 1294 of the mixing actuator rod 1290. Thus, asdescribed in detail above, the safety lock 1700 can be moved in thedirection of the arrow DD in FIG. 57 to move the lock arms 1706 of thelock portion 1705 of the safety lock 1700 past the lock member 1730(e.g., the movement of the safety lock 1700 passes the lock member 1730through an opening (not shown) substantially circumscribed by the tabs1708 of the lock arms 1706. As such, the safety lock 1700 can be removedfrom the housing 1100.

When the safety lock 1700 is moved from its first position to its secondposition (i.e., removed from the housing 1100), the electronicactivation protrusion 1720 is likewise moved relative to the housing1100. More specifically, the safety lock 1700 removes the electronicactivation protrusion 1720 from the notch 1922 defined by the printedcircuit board 1920 and out of contact and/or engagement with the firstswitch 1925 when moved to its second position. As such, the first switch1925 can transition from a first state to a second state (e.g., closesan electric circuit or the like). The transition of the first switch1925 to its second state can, for example, result in the electroniccircuit system 1900 outputting one or more predetermined electronicoutputs. For example, a processor (not shown) can output an electronicsignal associated with recorded speech to the audio output device 1930.Such an electronic signal can be, for example, associated with arecorded message notifying the user of the status of the medicalinjector 1000. Such a status message can state, for example, “The needleguard has been removed and the mixing operation is in process,” or“mixing complete.” The electronic circuit system 1900 can alsosimultaneously output an electronic signal to one or more of the LEDs1940, thereby causing one or more LEDs 1940 to start flashing, stopflashing, change color, and/or the like. In some embodiments, thehousing can include a display such as a liquid crystal display (LCD), alight emitting diode (LED) display, and/or similar display that cangraphically represent a visual status of the medical injector 1000and/or the medicament prior to, during, and/or after mixing.

In some embodiments, the first switch 1925 and the electronic activationprotrusion 1720 can be configured such that the electronic activationprotrusion 1720 moves a predetermined distance before the electronicactivation protrusion 1720 is removed from engagement with the firstswitch 1925. For example, in some embodiments, the electronic activationprotrusion 1720 can move approximately 0.62 inches before the electronicactivation protrusion 1720 disengages the first switch 1925. In thismanner, the safety lock 1700 can be moved slightly without transitioningthe first switch 1925 of the electronic circuit system 1900 to thesecond state. Accordingly, this arrangement will permit the user toinadvertently and/or accidentally move the safety lock 1700 withoutactuating the electronic circuit system 1900.

In some embodiments, as described above, the electronic circuit system1900 can produce a recorded speech output instructing the user to “shakethe device for at least five seconds.” When the electronic circuitsystem 1900 detects changes in acceleration due to rapid or “shaking”motion, the electronic circuit system 1900 can initiate a countdowntimer. Moreover, when the electronic circuit system detects that shakinghas stopped prior to the completion of the timer period, the voiceprompt can pause or stop the countdown timer, and only resume when theshaking has resumed.

In some embodiments, the electronic circuit system 1900 can beconfigured to output the status message for a predetermined time, suchas, for example, five seconds. After the predetermined time has elapsed,the electronic circuit system 1900 can output an audible message furtherinstructing the user in the operation of the medical injector 1000. Suchan instruction can state, for example, “The mixing operation is nowcomplete. Place the base of the auto-injector against the patient'sthigh. To complete the injection, press the base firmly against thepatient's thigh.” In some embodiments, the electronic circuit system1900 can simultaneously output an electronic signal to one or more ofthe LEDs 1940, thereby causing one or more of the LEDs 1940 to flash aparticular color. In this manner, the electronic circuit system 1900 canprovide both audible and/or visual instructions to assist the user inthe placement and actuation of the medical injector 1000. In someembodiments, the electronic circuit system 1900 can be configured torepeat the instructions after a predetermined time has elapsed. In otherembodiments, the output associated with the completion of the mixingoperation (or any other operations described herein) need not be basedon an elapsed time. For example, as described above, some suchembodiments, the electronic circuit system 1900 can produce an outputwhen the mixing event has ended based at least in part upon the locationof a plunger within the medicament container.

In some embodiments, the medical injector 1000 can have a networkinterface device (not shown) configured to operatively connect theelectronic circuit system 1900 to a remote device (not shown) and/or acommunications network (not shown), as described above. In this manner,the electronic circuit system 1900 can send a wireless signal notifyinga remote device that the safety lock 1700 of the medical injector 1000has been removed and that the medical injector 1000 has been armed. Inother embodiments, the electronic circuit system 1900 can send awireless signal (e.g., a wireless 911 call) notifying an emergencyresponder that the medical injector 1000 has been armed. In yet otherembodiments, the wireless signal can be sent after medicament deliveryis detected by an audible signal, a mechanical switch, and/or otherelectronic sensor that provides status indication and subsequent signaldetection during medicament delivery.

In addition to activating the electronic circuit system 1900, removal ofthe safety lock 1700 also initiates the mixing operation. Specifically,the movement of the safety lock 1700 from the first position to thesecond position moves the lock rod 1715 relative to the housing 1100.More specifically, the movement of the safety lock 1700 removes the lockrod 1715 from contact with the lock portion 1275 of the carrier 1260,thereby enabling movement of the medicament container assembly 1200. Asdescribed above, when the safety lock 1700 is coupled to the housing1100, a portion of the lock rod 1715 is disposed in a space definedbetween the first member 1276 and the second member 1278 of the lockportion 1275 of the carrier 1260. Thus, the lock rod 1715 maintains thetab 1277 of the first member 1276 and the tab 1279 of the second member1278 in its corresponding carrier lock aperture 1113 defined by thehousing 1100. With the safety lock 1700 removed from the housing 1100,however, the lateral force exerted by the lock rod 1715 that maintainsthe carrier 1260 in its first position is removed. As such, the forceexerted by the bias member 1295 is sufficient to overcome a frictionforce between the tabs 1277 and 1279 and their corresponding surface ofthe housing 1100 (as described above) and/or is otherwise sufficient todeform the lock portion 1275 such that the tabs 1277 and 1279 areremoved from the carrier lock apertures 1113. As a result, the forceexerted by the bias member 1295 on the flange 1262 of the mixing portion1261 of the carrier 1260, moves the carrier 1260 in the direction of thearrow EE in FIG. 5.

As shown in FIGS. 58-60, the bias member 1925 moves the carrier 1260 inthe proximal direction as indicated by the arrow EE in FIG. 59 and thearrow FF in FIG. 60. The proximal movement of the carrier 1260 similarlymoves the medicament container 1210 in the proximal direction. Morespecifically, as shown in FIGS. 56 and 58, the medicament container 1210is disposed within the housing 1100 such that the mixing protrusion 1162of the proximal cap 1160 is adjacent to or in contact with the proximalor first elastomeric member 1220. Prior to the bias member 1295 being“released” (i.e., by disengagement of the tab 1277 and the tab 1279 fromthe housing 1100) to move the carrier 1260 in the proximal direction,the distal end portion 1212 of the medicament container 1210 is incontact with and/or otherwise engages the first shoulder 1270 of thecontainer mounting portion 1265 of the carrier 1260. This is shown inFIG. 58, which shows the medical injector in its third configuration(i.e., just after removal of the safety lock 1700, but with the needle1240 not yet in fluid communication with the medicament container 1210).

When carrier 1260 and/or the bias member 1295 is released, the forceexerted by the bias member 1295 begins to move the carrier 1260 in theproximal direction. The arrangement of the medicament container 1210 issuch that the carrier 1260 moves in the proximal direction relative tothe medicament container 1210. Specifically, with the mixing protrusion1162 of the proximal cap 1160 in contact with the first elastomericmember 1220, a force to move the carrier 1260 relative to the medicamentcontainer 1210 (e.g., a force to retract the first shoulder 1270 along alength of the medicament container 1210) eventually becomes less than aforce needed to continue movement the first elastomeric member 1220relative to the medicament container 1210. In other words, at thisjuncture in the mixing operation, the medicament container 1210 istemporarily maintained in a fixed position relative to the housing 1100while the carrier 1260 moves in the proximal direction. Thus, asdescribed below, during the initial stage of the mixing event, themedicament container 1210 moves relative to the carrier 1260 to placethe needle 1240 in fluid communication with the medicament container1210 (i.e., placing the medical injector 1000 into its fourthconfiguration, also referred to as the “priming” or “venting”configuration).

Specifically, after the carrier 1260 has moved a predetermined distancein the proximal direction and relative to the medicament container 1210and after the elastomeric members 1220 and 1221 have moved within themedicament container 1210 (see e.g., FIG. 59), a portion of themedicament container 1210 is moved into contact with the second shoulder1271 of the carrier 1260. Thus, as shown in FIG. 59, the distal cap 1216of the medicament container 1210 is disposed in the volume defined bythe second portion 1268 of the inner surface 1266 of the containermounting portion 1265. In addition, the proximal movement of the carrier1260 relative to the medicament container 1210 concurrently moves theneedle 1240 relative to the medicament container 1210 such that theproximal end portion 1241 of the needle 1240 pierces the seal member1217 of the medicament container 1210 and thus, is placed incommunication with the dry medicament volume 1227. With the needle 1240in communication with the dry medicament volume 1227 of the medicamentcontainer 1210 (i.e., with the medicament container 1210 being disposedin a second position relative to the carrier 1260), trapped gas withinthe medicament container 1210 can be vented. Thus, after the safety lock1700 is removed, the medical injector 1000 is moved from its thirdconfiguration (FIG. 58) to its fourth configuration (FIG. 59, i.e., atthe beginning of mixing with the needle 1240 in fluid communication withthe medicament container 1210 to facilitate venting or priming).

Expanding further, the constituents in the diluent volume 1226 can be,for example, an incompressible fluid or the like while the constituentsof the dry medicament volume 1227 can include a substantiallyincompressible solid (which can include some amount of a compressiblegas). As such, the diluent volume 1226 can at least temporarily remainconstant in size during the mixing operation and thus, the medicamentcontainer 1210 can similarly move relative to the second elastomericmember 1221. Similarly stated, as shown in FIGS. 58 and 59, the firstelastomeric member 1220 and the second elastomeric member 1221 caninitially move together as the injector 1000 moves from its thirdconfiguration to its fourth configuration. The movement of the firstelastomeric member 1220 and the second elastomeric member 1221 (seeFIGS. 58 and 59) can compress and/or otherwise decrease the size of thedry medicament volume 1227 without expelling the dry and/or lyophilizedmedicament contained therein. When the medical injector 1000 reaches thefourth (or venting) configuration, a portion of a gas within the drymedicament volume 1227 is expelled or vented therefrom via the needle1240.

As the medical injector 1000 moves from the third configuration (FIG.58) to the fourth configuration (FIG. 59), the medicament container 1210and the carrier 1260 can move in the proximal direction to an extentthat substantially aligns the bypass 1214 with the second elastomericmember 1221, as shown in FIGS. 59 and 60. In this embodiment, the bypass1214 can extend along a length of the medicament container 1210 that isgreater that a length along which each elastomeric member 1220 and 1221extends. Thus, when the medicament container 1210 is moved in theproximal direction and the bypass 1214 is substantially aligned with thesecond elastomeric member 1221, the increased pressure within thediluent volume 1227 urges a flow of the fluid diluent through the bypass1214 and around the second elastomeric member 1221 to be transferredinto the dry medicament volume 1227. In this manner, the fluid diluentcan mix with the lyophilized medicament disposed within the drymedicament volume 1227 to reconstitute the medicament for injection.

Further proximal movement of the carrier 1260 moves the medicamentcontainer 1210 in the proximal direction, as indicated by the arrow EEin FIG. 59 and the arrow FF in FIG. 60, thereby moving the medicalinjector 1000 from its fourth (or venting) configuration (FIG. 59) toits fifth configuration (FIG. 60, with mixing completed). Moreparticularly, as shown in FIG. 60, when the medicament container 1210 isthe second position relative to the carrier 1260, the carrier 1260 andthe medicament container 1210 move concurrently relative to the housing1100. With the mixing protrusion 1162 of the proximal cap 1160 beingdisposed in contact with the first elastomeric member 1220, the proximalmovement of the carrier 1260 and medicament container 1210 is, forexample, relative to the mixing protrusion 1162 and at least the firstelastomeric member 1220. Thus, the proximal movement of the medicamentcontainer 1210 with the carrier 1260 completes the mixing event, asshown in FIGS. 59 and 60. The arrangement of the elastomeric members1220 and 1221 within the medicament container 1210 is such that as themedicament container 1210 is moved in the proximal direction relative tothe housing 1100, the elastomeric members 1220 and 1221 move within themedicament container 1210 (as shown in FIGS. 59 and 60).

Referring to FIG. 60, the medicament container 1210, the carrier 1260,and the second elastomeric member 1221 can collectively move in theproximal direction relative to the first elastomeric member 1220 untilsubstantially all of the fluid diluent previously disposed in thediluent volume 1226 is transferred to the dry medicament volume 1227(which now becomes a reconstituted medicament volume), thereby placingthe medical injector 1000 in the fifth configuration (completion ofmixing). Although the medical injector 1000 is shown and described asbeing configured to purge at least a portion of gas contained in the drymedicament volume 1227 via the needle 1240, in other instances, themixing event can purge all or substantially all of the gas contained inthe dry medicament volume 1227 and, once purged, can similarly purge arelatively small volume of the reconstituted medicament.

In addition to facilitating venting and mixing, the proximal movement ofthe medicament container 1210 and the carrier 1260 is such that aportion of the medicament container assembly 1200 visible via the statusindicator apertures 1107 defined by the housing 1100 is changed. Forexample, as shown in FIGS. 56, 58, and 59, the second elastomeric member1221 is viewable via the status indicator apertures 1107 when themedical injector 1000 is in the first, second, and third configuration.As shown in FIG. 60, however, the proximal movement of the medicamentcontainer 1210, the second elastomeric member 1221, and the carrier 1260is such that the distal end portion 1212 of the medicament container1210 is viewable via the status indicator aperture 1107 and theelastomeric members 1220 and 1221 are obstructed by the housing 1100and/or otherwise not aligned with the status indicator apertures 1107.Thus, a user can visually inspect the medicament container assembly 1200to determine if the diluent volume 1226 was properly mixed with the drymedicament volume 1227. Thus, the user is guided not only by the outputfrom the electronic circuit system 1900, but also by the mechanicalvisual indicators.

After the mixing event, the medical injector 1000 can be moved from thefifth configuration (FIG. 60) to a sixth configuration (i.e., thebeginning of the injection event with the needle insertion operationcomplete, as shown in FIGS. 61 and 62). For example, as shown in FIG.61, once the mixing event is complete, the medical injector 1000 can bemanipulated to be placed in the first orientation (i.e., with the distalend 1242 of the needle 1240 pointed downward), as shown in FIG. 61. Insome instances, the electronic circuit system 1900 can be configured tonotify the user when the mixing event is completed. Moreover, in someembodiments, the orientation sensor and/or accelerometer can produce asignal associated with the orientation of the medical injector 1000after completion of the mixing event. Thus, in some embodiments, theelectronic circuit system 1900 can produce an output notifying the userof the orientation of the device (e.g. “To inject, turn the deviceupside down”) and can repeat this output until the medical injector 1000is placed in a correct orientation. In some embodiments, the mixingevent can purge a small volume of reconstituted medicament, which can inturn, visually indicate that the mixing event is complete. In stillother embodiments, the rate at which the mixing event occurs can besufficiently fast to an extent that the mixing event is complete by thetime the medical injector 1000 is placed in the fifth configuration.

As shown in FIGS. 61 and 62, once the medical injector 1000 isreoriented, the base 1510 is moved from a first position to a secondposition to place the medical injector 1000 in the fifth configuration.Similarly stated, the medical injector 1000 can be actuated by thesystem actuator assembly 1500 by moving the base 1510 proximallyrelative to the housing 1100. The base 1510 is moved from its firstposition to its second position by placing the medical injector 1000against a target surface (e.g., the body of the patient) and moving thebase 1510 with respect to the housing 1100 in the proximal direction, asindicated by the arrow GG in FIG. 61.

When the base 1510 is moved from the first position to the secondposition, the system actuator assembly 1500 actuates and/or otherwisereleases the release member 1550 (as described below) and also moves theelectronic activation protrusion 1520 relative to the housing 1100. Moreparticularly, the electronic activation protrusion 1520 is moved in aproximal direction and into contact and/or engagement with the secondswitch 1926 of the electronic circuit system 1900. As such, the secondswitch 1926 can be transitioned from its first electric state to itssecond electric state. In some instances, the transition of the secondswitch 1926 to the second electric state can be operable in causing theelectronic circuit system 1900 to perform one or more tasks such asoutputting an audio output via the audio output device 1930 and/or avisual output via the one or more LEDs 1940, as described in detailabove.

In addition to activating the second switch 1926, the proximal movementof the base 1510 from its first position to its second position actuatesand/or otherwise releases the release member 1550. As such, the spring1565 is allowed to transition from a first configuration (e.g., acompressed configuration) to a second configuration (e.g., anon-compressed configuration), thereby moving the release member 1550within the gas cavity 1132. More specifically, the proximal movement ofthe base 1510 moves the release rod 1530 in the proximal directionwithin the housing 1100, thereby placing the engagement surface 1534 ofthe proximal end portion 1531 of the release rod 1530 in contact withthe first extension 1554 and the second extension 1556 disposed at ornear the distal end portion 1552 of the release member 1550. As such,the engagement surface 1534 engages the extensions 1554 and 1556 and asa result reduces a distance therebetween (e.g., reduces the opening1558). More specifically, the engagement surface 1534 engages the firstextension 1554 and the second extension 1556 to disengage and/orotherwise remove the projections 1555 and 1557, respectively, from thedistal wall 1133 of the gas cavity 1132. With the projections 1555 and1557 disengaged from the distal wall 1133, the force exerted by thespring 1565 can move the release member 1550 in the proximal directionsuch that the projections 1555 and 1557 pass through the opening 1134defined by the distal wall 1133, as shown in FIG. 62. Similarly stated,when the base 1510 is moved in the proximal direction, the engagementsurface 1534 disengages the release member 1550, thereby allowing thespring 1565 to transition from its first configuration to its secondconfiguration, as indicated by the arrow HH in FIG. 62.

With the base 1510 placed in its second position and with the releasemember 1550 disengaged from the distal wall 1133, the spring 1565 movesthe release member 1550 in the proximal direction to cause the puncturer1570 to puncture and/or pierce a portion of the gas container 1580(e.g., a frangible seal or the like). After the gas container 1580 hasbeen punctured, an actuating portion of a compressed gas flows from thegas container 1580 and into the gas cavity 1132. Moreover, with the seal1560 of the release member 1550 forming a substantially fluid tight sealwith the inner surface 1130 defining the gas cavity 1132, the actuatingportion of the compressed gas fills the gas cavity 1132 and is forcedthrough the gas passageway 1104 defined by the housing 1100 and into themedicament cavity 1141.

As the gas flows into the medicament cavity 1141, the gas applies gaspressure to the flange 1230 of the medicament container 1210 and thefirst elastomeric member 1220 within the medicament container 1210. Morespecifically, the seal member 1235 disposed about the flange 1230coupled to the proximal end portion 1211 of the medicament container1210 forms a substantially fluid tight seal with a portion of the innersurface 1130 defining the medicament cavity 1141. The seal member 1236(i.e., the inner seal) forms a substantially fluid tight seal with aninner portion of the flange 1230 that defines at least a portion of themedicament cavity 1141. Thus, the pressure within the medicament cavity1141 increases as a volume of the gas disposed in the medicament cavity1141 increases. Once the pressure within the medicament cavity 1141reaches an amount that provides enough force to overcome the staticfriction, that force on the flange 1230 moves the medicament container1210 and the carrier 1260 in the distal direction, as indicated by thearrow II in FIG. 62. More particularly, the force exerted to move themedicament container 1210 (the insertion force) is a function of thepressure within the medicament cavity 1141 and the surface area of theflange 1230. The force exerted to produce injection (the injectionforce, which moves the elastomeric members within the medicamentcontainer 1210) is a function of the pressure within the medicamentcavity 1141 and the surface area of the first elastomeric member 1220.Thus, the relative sizes of the flange 1230 and the first elastomericmember 1220 are selected such that the insertion force is sufficient toproduce needle insertion (FIGS. 61 and 62) before the injection forcereaches a threshold sufficient to produce delivery of the medicament(FIG. 63).

In some instances, the gas pressure within the medicament cavity 1141can exert an insertion force sufficient to overcome a reaction forceexerted by the bias member 1295 of the medicament container assembly1200. In response to the insertion force, the medicament container 1210,the carrier 1240 and the needle 1240 contemporaneously move within thehousing 1100 in the distal direction. The movement of the needle 1240 ina distal direction causes the distal end portion 1242 of the needle 1240to exit the housing 1100 and enter the body of a patient prior toadministering the medicament, thereby placing the medical injector 1000in the sixth configuration. The insertion force associated with the gaspressure causes the carrier 1260 and the medicament container 1210 tomove within the medicament cavity 1141 a predetermined distance (tofacilitate needle insertion). In some embodiments, the predetermineddistance can be associated with a position at which the carrier 1260 isin contact with the housing 1100, thereby completing the needleinsertion operation. As such, further distal movement of the carrier1260, the medicament container 1210 and/or the needle 1240 issubstantially prevented.

With the medicament container 1210 in a distal position (the needlefully inserted), the gas within the medicament cavity 1141 continues toapply gas pressure to the medicament container 1210 including a proximalsurface of the first elastomeric member 1220. Thus, when the gaspressure within the medicament cavity 1141 exceeds a given threshold,the gas pressure exerts an injection force on the first elastomericmember 1220 sufficient to move the first elastomeric member 1220 in thedistal direction within the medicament container 1210. As shown in FIG.62, the first elastomeric member 1220 can be in contact with the secondelastomeric member 1221 such that the gas pressure exerts a forcesufficient to move both the elastomeric members 1220 and 1221 in thedistal direction. The distal movement of the elastomeric members 1220and 1221 generates a pressure upon the medicament contained within themedicament container 1210, thereby allowing at least a portion of themedicament to flow out of the medicament container 1210 via the needle1240, as indicated by the arrow JJ in FIG. 63. Furthermore, when theelastomeric members 1220 and 1221 are disposed in a distal positionwithin the medicament container 1210, the medical injector 1000 hasdelivered a dose of the reconstituted medicament. As such, the medicalinjector 1000 is placed in the seventh configuration (FIG. 63). Asshown, the injection (or delivery) operation is completed solely via thegas pressure exerting a force against the elastomeric members 1220 and1221, without a physical piston or rod contacting the elastomericmembers 1220 and 1221.

As shown in FIGS. 64 and 65, after the medical injector 1000 deliversthe reconstituted medicament, the gas pressure within the medicamentcavity 1141, the gas cavity 1132, and/or the gas container 1580 cansubstantially equalize or be reduced to facilitate needle retraction.Similarly stated, after medicament injection, the medical injector 1000can be moved from the seventh configuration (FIG. 63) to an eighthconfiguration (needle retraction). In some embodiments, the distalmovement of the medicament container assembly 1200 can be such that avolume of at least the medicament cavity 1141 is increased to an extentthat the gas pressure therein is decreased below a predeterminedthreshold. After the gas pressure within the medicament cavity 1141and/or gas cavity 1132 is equalized and/or otherwise falls below apredetermined threshold, the reaction force exerted by the bias member1295 in response, for example, to being compressed under the gaspressure is sufficient to overcome a remaining force associated with thedecreased gas pressure, thereby allowing the bias member 1295 totransition toward its biased (e.g., non-compressed) configuration. Inthis manner, the bias member 1295 exerts a force on the flange 1262 ofthe carrier 1260 to cause the carrier 1260 to move proximally within thehousing 1100 (i.e., to retract). Thus, after the injection event, thedistal end portion 1242 of the needle 1240 can be automaticallyretracted in the housing 1100, thereby placing the medical injector 1000in the eighth configuration, as indicated by the arrow KK in FIG. 65.Moreover, it is noted that the bias member 1295 functions to produce aforce at a first time to move the carrier 1260 proximally to producemixing and produce a force at a second time to move the carrier 1260proximally to retract the needle.

In some embodiments, the medical injector 1000 can include a gas releasevalve and/or the like configured to vent or release a portion of gasafter the medical injector 1000 is placed in the seventh configuration.In some such embodiments, the gas release valve can be an “active” valvethat is actuated only after the injection is completed (after themedical injector 1000 is placed in the seventh configuration). Forexample, in some embodiments, the medicament container 1210 can includevalve or other structure (e.g., a vent that is gas permeable, but liquidimpermeable) that is actuated or otherwise exposed when one of the firstelastomeric member 1220 or the second elastomeric member 1221 movesbeyond a particular position within the medicament container 1210 (e.g.,the movement as shown in FIGS. 62 and 63). In other embodiments, the gasrelease valve can be a passive mechanism that is always opened. Forexample, in some embodiments, the flange 1230 includes a passageway ororifice (not shown) that permits a continuous “bleed” of air pressurefrom the medicament cavity 1141. In such embodiments, the passageway canbe sized such that the release of gas pressure is at a low enough rateto ensure sufficient gas pressure to produce the desired insertion andinjection force, while being at a high enough rate to facilitateretraction after completion of the injection. Although the passageway ororifice is described as being defined by the flange 1230, in otherembodiments, a suitable portion of the medical injector 1000 can definesuch a passageway (e.g., the housing 1100, the proximal cap 1160, therelease member 1550, and/or the like).

The retraction of the carrier 1260 results in a change in a portion ofthe medicament container assembly 1200 that is viewable via the statusindicator apertures 1107. Thus, the user can visually inspect themedicament container assembly 1200 to determine if the injection eventis complete. In addition, as described above, the protrusion 1520 of thebase 1510 actuates the second switch 1925 of the electronic circuitsystem 1900 when the base 1510 is moved in the proximal direction. Insome embodiments, the electronic circuit system 1900 can be configuredto trigger a predetermined output or sequence of outputs when themedicament container assembly 1200 is moved its retracted position. Forexample, the electronic circuit system 1900 can output an audio messageafter a predetermined time following the activation of the second switch1926. Such an audio message can state, for example, “The injection isnow complete. Please seek further medical attention from a doctor.” Inother embodiments, a record speech output can include a “countdown”timer instruct the user on how long the user should maintain theinjection device 1000 in contact with the target location. Theelectronic circuit system 1900 can also simultaneously output anelectronic signal to one or more LEDs 1940, thereby causing one or moreLEDs 1940 stop flashing, change color, and/or the like to provide avisual indication that the injection is complete. In other embodiments,the electronic circuit system 1900 can send a wireless signal notifyinga remote device that the injection is complete. In this manner, apatient's compliance and/or adherence with the use of the system can bemonitored.

Once the needle 1240 is retracted into the housing 1100 and theelectronic circuit system 1900 has output a corresponding audio and/orvisual output, the medical injector 1000 or at least a portion thereofcan be disposed of. For example, in some embodiments, the medicalinjector 1000 is a single use device, which can be safely disposed of inits entirety after use. In other embodiments, only a portion of themedical injector 1000 is disposable. For example, after use, the medicalinjector 1000 can be manipulated to remove, for example, the medicamentcontainer 1210, the carrier 1260, and the substantially empty gascontainer 1580, which can then be replaced with an unused and sterilizedmedicament container and carrier including an unused needle sheath, andan unused gas container. In addition, the release member 1550 and thebase 1510 of the system actuator assembly 1500 and the bias member 1295of the medicament container assembly 1200 can be reset (e.g., placed ina pre-actuated configuration in which the bias member 1295 and thespring 1565 have a relatively high potential energy and/or are otherwisecompressed or “loaded”). Once completed, the medical injector 1000 canbe manipulated to replace and/or reposition the safety lock 1700 and thecover 1180. The arrangement of the electronic circuit system 1900 can besuch that when, for example, the system actuator assembly 1500 is resetand the safety lock 1700 and case 1180 are replaced, the electroniccircuit system 1900 is similarly reset. Specifically, since the firstswitch 1925 and the second switch 1926 are reversible switches, theresetting of the medical injector 1000 as described above, places boththe first switch 1925 and the second switch 1926 in its respective firststate. Thus, at least a portion of the medical injector 1000 can bereusable.

While various embodiments have been described above, it should beunderstood that they have been presented by way of example only, and notlimitation. Where schematics and/or embodiments described above indicatecertain components arranged in certain orientations or positions, thearrangement of components may be modified. While the embodiments havebeen particularly shown and described, it will be understood thatvarious changes in form and details may be made. Although variousembodiments have been described as having particular features and/orcombinations of components, other embodiments are possible having acombination of any features and/or components from any of embodiments asdiscussed above.

For example, although the safety member 2700 is shown and described ashaving a lock protrusion 2706 and the safety member 3700 is shown anddescribed as having a first portion 3715 that actuates an energy storagemember, in some embodiments, a safety member can include a lockprotrusion similar to the lock protrusion 2706 and an actuation portionsimilar to the first portion 3715. In some embodiments, any of thesafety members described herein can include an electronics actuationportion similar to the electronic activation protrusion 1720 of thesafety lock 1700. In some embodiments, any of the safety membersdescribed herein can include a needle sheath engagement portion similarto the needle sheath aperture 1725 and related structure of the safetylock 1700.

Although the electronic circuit system 1900 is shown and described asincluding one or more switches having two states, in other embodiments,and electronic circuit system can include any suitable switch having anysuitable number of states. Similarly stated, in some embodiments, any ofthe switches described herein can be any electronic component (e.g.,resistor) that senses a change in conditions (e.g., a pressure exerted,a break in the circuit, or the like) and produces a signal.

Where methods and/or events described above indicate certain eventsand/or procedures occurring in certain order, the ordering of certainevents and/or procedures may be modified. Additionally, certain eventsand/or procedures may be performed concurrently in a parallel processwhen possible, as well as performed sequentially as described above. Forexample, although the medical injector 1000 is shown and described ascompleting the mixing operation in two distinct phases (i.e., as movingto the fourth and fifth configurations), in some embodiments, theventing (or priming) operation and the mixing of the diluent and thesolid medicament can be included in a single operation. Similarlystated, in some embodiments, the mixing of diluent can begin before theneedle is placed in fluid communication with the medicament containerand/or before the gas is purged.

Although the medicament delivery devices described herein are configuredto initiate a mixing and/or venting operation when being placed in thedevice is placed is a predetermined orientation, in other embodiments, amedicament delivery device need not be disposed in a predeterminedorientation to allow and/or initiate mixing and/or venting. For example,while the safety lock 1700 is shown and described herein as beingmaintained in a substantially fixed position relative to the housing1100 until the medicament delivery device 1000 is placed in apredetermined orientation (e.g., pointing upward), in other embodiments,the safety lock 1700 can selectively engage the housing 1100 in anysuitable manner such that removal of the safety lock 1700 from thehousing 1100 actuates and/or initiates a mixing operation.

Although the medicament delivery devices are shown and described hereinas being medical injectors having a medicament container divided intotwo portions (see e.g., the medical injector 1000), in otherembodiments, any of the components, methods and/or formulationsdescribed herein can be used in any suitable medicament delivery device,such as, for example, an auto-injector, a pen injector, an inhaler,patch-pump, a nasal delivery system or the like. In some embodiments,the medicament delivery device can include a medicament container havingany number of plungers and/or defining any number of volumes therein.

Although the medicament container 1210 is shown as being initiallyspaced apart from and/or fluidically isolated from the needle 1240, inother embodiments, a medical injector 1000 can include a medicamentcontainer that has a staked needle. For example, in some embodiments, amedical injector 1000 includes a prefilled syringe in which the needleis in fluid communication with the medicament container. In suchembodiments, the mixing operation need not, therefore, place thecontainer in fluid communication with the needle.

Although the components and methods described herein are shown anddescribed as being included in devices that include a medicament, inother embodiments, any of the components and/or methods described hereincan be used in either an actual medicament delivery device or asimulated medicament delivery device. A simulated medicament deliverydevice, for example, can correspond to an actual medicament deliverydevice and can facilitate the training of a user in the operation of thecorresponding actual medicament delivery device. A simulated medicamentdelivery device or trainer can be similar to the simulated medicamentdelivery devices or trainers described in U.S. Patent Publication Number2008/0059133, entitled “Medical Injector Simulation Device,” filed Feb.27, 2007, which is incorporated herein by reference in its entirety.

In such embodiments, the simulated medicament delivery device cansimulate the actual medicament delivery device in any number of ways.For example, in some embodiments, the simulated medicament deliverydevice can have a shape corresponding to a shape of the actualmedicament delivery device, a size corresponding to a size of the actualmedicament delivery device and/or a weight corresponding to a weight ofthe actual medicament delivery device. Moreover, in some embodiments,the simulated medicament delivery device can include components thatcorrespond to the components of the actual medicament delivery device.In this manner, the simulated medicament delivery device can simulatethe look, feel, forces, and sounds of the actual medicament deliverydevice. For example, in some embodiments, the simulated medicamentdelivery device can include external components (e.g., a housing, aneedle guard, a sterile cover, a safety lock or the like) thatcorrespond to external components of the actual medicament deliverydevice. In some embodiments, the simulated medicament delivery devicecan include internal components (e.g., an actuation mechanism, acompressed gas source, a medicament container or the like) thatcorrespond to internal components of the actual medicament deliverydevice.

In some embodiments, however, the simulated medicament delivery devicecan be devoid of a medicament and/or those components that cause themedicament to be delivered (e.g., a needle, a nozzle or the like). Inthis manner, the simulated medicament delivery device can be used totrain a user in the use of the actual medicament delivery device withoutexposing the user to a needle and/or a medicament. Moreover, thesimulated medicament delivery device can have features to identify it asa training device to prevent a user from mistakenly believing that thesimulated medicament delivery device can be used to deliver amedicament. For example, in some embodiments, the simulated medicamentdelivery device can be of a different color than a corresponding actualmedicament delivery device. Similarly, in some embodiments, thesimulated medicament delivery device can include a label and/or otherindicia clearly identifying it as a training device.

Although the electronic circuit system 1900 is shown and described aboveas having two reversible switches (e.g., switch 1925 and switch 1926),in other embodiments, an electronic circuit system can have any numberof switches. Such switches can be either reversible or irreversible.Although the electronic circuit system 1900 is shown and described aboveas producing an electronic output in response to the actuation of thetwo switches 1925 and 1926, in other embodiments, an electronic circuitsystem can produce an electronic output in response to any suitableinput, command or prompt. Suitable input for prompting an output caninclude, for example, an audible input by the user (e.g., the user'sresponse to a voice prompt produced by the electronic circuit system),an input from a “start button” depressed by the user, an input from asensor (e.g., a proximity sensor, a temperature sensor or the like),movement of (e.g., shaking) of the medicament delivery device, or thelike. In some embodiments, an electronic circuit system can include amicrophone and/or a voice recognition module to detect a user's vocalinput, an electronically produced input, or other sound to process andcause a subsequent action. In some embodiments, the electronic circuitsystem 1900 can include a “configuration switch” (similar to any of theswitches shown and described above, such as the switch 1925) that, whenactuated during the assembly of the delivery device, can select anelectronic output corresponding to a dose contained within themedicament container (e.g., 0.4 mg, 0.8 mg, 1.0 mg, 1.6 mg, 2.0 mg, ormore).

Although the electronic circuit system 1900 includes three LEDs 1940 andthe audio output device 1930, in other embodiments a medical device canhave any number of LEDs and/or audio output devices. Additionally, othertypes of output devices, such as haptic output devices, can be used. Insome embodiments, outputs from an electronic circuit system can include,for example, an audible or visual output related to the composition ofthe medicament (e.g., an indication of the expiration date, the symptomsrequiring treatment with the medicament or the like), the use of themedicament delivery device, and/or post-administration procedures (e.g.,a prompt to call 911, instructions for the disposal of the device or thelike).

In some embodiments, the audible sound produced by any of the devicesshown and described herein can be produced in conjunction with one ormore visual outputs. For example, in some embodiments, a medicamentdelivery device can include a video screen (e.g., an LCD screen) uponwhich messages, videos and/or other instructions can be shown during useof the device. In some embodiments, the device can include a touchscreen such that, in addition to the feedback from the movement ofvarious components of the device (e.g., the carrier) as describedherein, the electronic circuit system can receive input directly fromthe user.

Although the electronic circuit system 1900 is shown and described aboveas being actuated by the removal of the cover 1180 and/or the movementof the system actuator assembly 1500, in other embodiments, anelectronic circuit system can be actuated by any suitable mechanism. Insome embodiments, for example, a medicament delivery device can includea movable battery clip, an on/off switch or the like that can bemanipulated by the user to actuate the electronic circuit system. Insome embodiments, for example, a medical injector need not have a coversimilar to the cover 1180; rather, the medical injector can be manuallyactuated by a “start” button depressed by the user. In some embodiments,the electronic circuit system 1900 of the types shown and describedherein can be used in either an actual medicament delivery device or asimulated medicament delivery device.

Although the carrier 1260 is shown and described above as receiving aportion of the medicament container 1210, in other embodiments, acarrier can substantially surround the medicament container 1210. Forexample, in some embodiments, a carrier can include a first portion anda second portion coupled by a hinge, such that the carrier can beconfigured between a first (opened) configuration and a second (closed)configuration. In this manner, the carrier 1260 can be configured toreceive at least a portion of the medicament container 1210 when in theopen configuration and can be moved to the closed configuration tosubstantially surround the medicament container 1210.

Although the carrier 1260 is shown and described as being coupled to theneedle 1240, in other embodiments, a device can include a carrier and/ormedicament container that is devoid of a needle. For example, in someembodiments, a medicament delivery device such as the medicamentdelivery device 1000 can be a needleless injector, which includes acarrier and/or medicament container that defines a pathway and/orotherwise coupled to a delivery member through which the medicament isconveyed upon actuation.

Although the mixing of the diluent volume 1226 and the dry medicamentvolume 1227 is shown and described above as being actuated and/orinitiated by the removal of the safety lock 1700 from the housing 1100,in other embodiments, a mixing operation can be actuated and/orinitiated by any suitable mechanism. For example, in some embodiments, amixing operation can be initiated by an actuator such as the systemactuator assembly 1500 being moved from a first position to a secondposition.

Any of the medicament containers described herein can be any containersuitable for storing the compositions disclosed herein. In someembodiments, the medicament container can be a pre-filled syringe, apre-filled cartridge, a vial, an ampule or the like. In someembodiments, for example, any of the devices shown and described hereincan include components and/or mechanisms to accommodate a pre-filledsyringe, similar to the embodiments shown and described in U.S. PatentPublication No. 2013/0023825 entitled, “Medicament Delivery Devices forAdministration of Medicament within a Prefilled Syringe,” filed Jan. 25,2012 the disclosure of which is incorporated herein by reference in itsentirety. In other embodiments, the medicament containers described herecan be a container having a flexible wall, such as, for example, abladder.

Any of the devices and/or medicament containers shown and describedherein can be included in a kit (not shown), which can include fungiblecomponents and reusable components. For example, in some embodiments, atleast a housing of a medical injector can be reusable without the needfor sterilization, as described in detail above. In some embodiments,such as with the medical injector 1000, the proximal cap 1160 can beremoved from the housing 1100 to allow access to and removal of the usedcomponents disposed within the housing 1100. In addition, the removal ofthe proximal cap 1160 from the housing 1100 can allow for any suitableportion of the medical injector 1000 to be reset to, for example, apre-activated or pre-actuated configuration, as described above.

Although the housing 1100 is shown and described above as beingmonolithically constructed and subsequently coupled to the proximal cap1160, in other embodiments, a medical injector can include a housinghaving multiple portions, which can allow for replacement of usedcomponents. For example, such a housing can include a first portion orside matingly coupled to a second portion or side. In such embodiments,the housing can include one or more seal members or the like that can bedisposed between mating surfaces of the first portion and secondportion. Thus, the coupled portions of such a housing can collectivelydefine a gas cavity, a medicament cavity, and a mixing actuator cavitysimilar to the gas cavity 1132, the medicament cavity 1141, and themixing actuator cavity 1142, respectively, of the housing 1100. Thus,such a housing can allow access to an inner volume of collectivelydefined by the portions of the housing to allow a user to replace usedcomponents with unused components and to reset actuated and/or activatedportions of such a device to un-actuated and/or un-activatedconfigurations.

Moreover, in some embodiments, such a medical injector can be packagedwith and/or otherwise included in a kit, which contains, for example,the reusable portions of that medical injector (e.g., a housing, asystem actuator, and electronic circuit system, a safety lock, a case,and/or the like) and fungible portions of that medical injector (e.g., amedicament container, a carrier, a gas container, and/or the like). Insome embodiments, the kit can include one reusable portion of thatmedical injector and any number of fungible portions of that medicalinjector included one fungible portion pre-assembled and stored in thereusable portion (e.g., the housing).

Any of the devices and/or medicament containers shown and describedherein can be constructed from any suitable material. Such materialsinclude glass, plastic (including thermoplastics such as cyclic olefincopolymers), or any other material used in the manufacture of prefilledsyringes containing medications.

Although the medical injector 1000 is shown and described above asincluding portions of the medicament container assembly 1200 as beingactuated by the expansion of a compressed gas, in other embodiments,such portions of a medicament container and/or any other portion of amedical injector can be actuated by a spring and/or any other suitablemember configured to exert a force. For example, in some embodiments, amedical injector can include a medicament container and a carrierconfigured to move in a distal direction in response to a force exertedby a spring. Conversely, while the medical injector 1000 is shown anddescribed above as including portions of the medicament containerassembly 1200 and/or the system actuator assembly 1500 as being actuatedby a spring, in other embodiments such portions of a system actuatorassembly and/or a medicament container assembly can be actuated by anexpansion of a compressed gas and/or the like. For example, while themixing of the diluent volume 1226 and the dry medicament volume 1227 isshown and described above as being activated and/or initiated by thebias member 1295, in other embodiments, an expansion of gas releasedfrom the gas container 1580 can activate and/or initiate a mixing event.In still other embodiments, a mixing portion of medical injector caninclude a gas container distinct from, for example, the gas container1580.

Any of the devices and/or medicament containers shown and describedherein can include any suitable medicament or therapeutic agent. Forexample, although the medical injectors described above are shown anddescribed is including a multi-chamber medicament container (e.g.,medicament container 1210) that includes a substantially dry medicament(e.g., contained within the dry medicament volume 1227) and a diluent(e.g., contained within the diluent volume 1226), in other embodiments,any of the medicament delivery devices disclosed herein can include amulti-chamber container that is filled with any suitable substances. Forexample, in some embodiments, any of the medicament delivery devicesdisclosed herein can include a medicament container (e.g., a cartridge)that separately stores and mixes, upon actuation, two liquid substances.For example in some embodiments, any of the devices shown and describedherein can include a medicament container filled with (in separatechambers) epinephrine and at least one antihistamine (e.g., epinephrineand diphenhydramine, epinephrine and hydroxyzine, epinephrine andcetirizine); an antipsychotic medicament and a benzodiazepine (e.g.haloperidol and diazepam, haloperidol and midazolam, haloperidol andlorazepam); insulin and a GLP-1 analog or incretin mimetic (e.g. insulinand exenatide, insulin and lixisenatide); an NSAID and an opiode (e.g.,ketorolac and buprenorphine). Other suitable compositions that can beincluded in any of the medicament containers and/or devices describedherein include pralidoxime chloride and atropine; obidoxime chloride andatropine; epinephrine and atropine; methotrexate and etanercept;methotrexate and adalimumab; and methotrexate and certolizumab.

Glucagon Formulation

In some embodiments, a composition can include glucagon and/or anypharmaceutically acceptable constituents for use in the medicamentdelivery devices disclosed herein. In some embodiments, the glucagonformulation can be prepared and/or filled according to any suitablemethod such as, for example, those described in U.S. Patent PublicationNo. 2013/0023822 incorporated by reference hereinabove. A compositionaccording to an embodiment can be formulated such that the targetconcentration of glucagon in the solution, either before lyophilizationand/or after being reconstituted upon actuation of the device, isapproximately 1 mg/mL. In other embodiments, the target concentration ofglucagon in the solution, either before lyophilization and/or afterbeing reconstituted, can be approximately 2 mg/mL, approximately 1.5mg/mL, approximately 0.5 mg/mL (e.g., a pediatric dose) or approximately0.25 mg/mL. In other embodiments, a composition can be formulated suchthat the target concentration of glucagon in the solution, either beforelyophilization and/or after being reconstituted upon actuation of thedevice, is between approximately 0.25 mg/mL and 2 mg/mL, betweenapproximately 0.5 mg/mL and 1 mg/mL, or between approximately 0.8 mg/mLand 1.2 mg/mL.

In certain embodiments, the concentration (either before lyophilizationor upon reconstitution) of glucagon in a glucagon formulation is about 1mg/mL and the total solute concentration is about 50 mg/mL. For example,in some embodiments, a composition can include glucagon and any suitablebulking agents to increase the total solute concentration in theglucagon formulation. In this manner, the glucagon formulation can bemore effectively lyophilized and/or reconstituted. For example, in someembodiments, as described below, certain bulking agents can be used toimprove the stability, solubility and/or efficacy of the compositionwhen reconstituted in any of the devices shown and described herein. Insome embodiments, certain bulking agents can be used to produce a visualindicia when the composition is reconstituted (e.g., such agents canallow the reconstituted medicament to be more easily detected by theuser).

In some embodiments, a composition can include a peptide, such as, forexample, glucagon and a carbohydrate. In this manner, the stability ofthe peptide (e.g., glucagon) can be increased during lyophilization andsubsequent storage. In particular, the stability of peptides, such asglucagon, can be increased in an amorphous (i.e. non-crystalline)environment. It is believed that carbohydrates undergoing dehydrationcreate a solid-state environment that is amorphous and exhibits highviscosity when maintained below the glass transition temperature. Inaddition, carbohydrates contain multiple hydroxyl groups that may formhydrogen bonds with polar groups on a protein or peptide surface in anamorphous solid-state environment. Without being bound by any particularmechanism, when water is removed during lyophilization, suchcarbohydrates may maintain the hydrogen bonds and preserve thenative-like solid state of the polypeptide structure. In certainembodiments, therefore, the glucagon formulations include otherexcipients, such as, but not limited to carbohydrates. Suitablecarbohydrates include, but are not limited to, lactose, trehalose,mannitol, and combinations thereof.

Additionally, the solubility of glucagon increases below a pH of 4. Incertain embodiments, the glucagon formulations, prior to lyophilizationand/or after reconstitution, have a pH of less than about pH 5.0,including less than about pH 4.5, less than about pH 4.0, less thanabout pH 3.5, less than about pH 3.0, less than about pH 2.5, less thanabout pH 2.0. In other embodiments of the invention, the glucagonformulations, prior to lyophilization and/or after reconstitution, havea pH range of about pH 1.5 to about pH 5.0, inclusive of all ranges andsubranges therebetween, e.g., about pH 2.0 to about pH 4.5, about pH 2.0to about pH 4.0, about pH 2.0 to about pH 3.5, about pH 2.0 to about pH3.0, about pH 2.0 to about pH 2.5, about pH 2.5 to about pH 4.5, aboutpH 2.5 to about pH 4.0, about pH 2.5 to about pH 3.5, about pH 2.5 toabout pH 3.0, about pH 3.0 to about pH 4.5, about pH 3.0 to about pH4.0, about pH 3.0 to about pH 3.5, about pH 3.5 to about pH 4.5, andabout pH 3.5 to about pH 4.0. In certain embodiments, the pH of theglucagon formulation is adjusted prior to lyophilization by the additionof a suitable acid, such as hydrochloric acid or citric acid.

The lyophilized formulations of the present invention may bereconstituted by any suitable diluent or combination of diluent,including, but not limited to, water, sterile water, glycerin, orhydrochloric acid.

As described above, in some embodiments, a glucagon formulation caninclude any suitable bulking agents and/or excipients. Table 1 lists theformulations investigated for lyophilization. The formulations set forthe below include a concentration of glucagon in the solution, eitherbefore lyophilization and/or after being reconstituted, of approximately1 mg/mL.

TABLE 1 Formulation Excipients and Concentration Medicament 1 Lactose -49 mg/mL 1 mg/mL glucagon 2 Trehalose - 40 mg/mL 1 mg/mL glucagonMannitol - 20 mg/mL 3 Trehalose - 40 mg/mL 1 mg/mL glucagon Mannitol -20 mg/mL Citric acid - 1.8 mg/mL Sodium citrate - 0.35 mg/mL 4 Glycine -20 mg/mL 1 mg/mL glucagon 5 Mannitol - 40 mg/mL 1 mg/mL glucagonAscorbic acid - 5 mg/mL

Formulation 1 included lactose, which is a known animal-derivedexcipient. Lactose, which is used in the commercially available glucagonformulations, is a reducing sugar that may destabilize glucagon.Accordingly, Formulations 2 through 5 are lactose-free formulations.Formulation 2 utilized trehalose and mannitol as carbohydrate bulkingagents. Formulation 3 included a buffer system of citric acid and sodiumcitrate, in addition to the carbohydrate bulking agents. Formulation 4was carbohydrate free, containing only glycine as the bulking agent.Formulation 5 utilized only mannitol as a bulking agent and includedascorbic acid. All formulations except Formulation 3 employedhydrochloric acid to reduce the solution pH to approximately 3 beforelyophilization.

Trehalose, however, is a non-reducing sugar, and without being bound byany particular mechanism, may potentially increase the stability ofglucagon, prior to lyophilization, during lyophilization, in storage,and/or after reconstitution. In addition to the improved properties ofFormulation 3, the absence of any animal-based excipients, such aslactose, make it particularly appealing from a regulatory standpoint, asthe FDA has strict guidelines regarding animal-based excipients.

All five formulations listed in Table 1 were successfully reconstitutedwith water and resulted in solutions suitable for use in themulti-chambered container closure system of the present invention.

In some embodiments, the medicament contained within any of themedicament containers shown herein can be a vaccine, such as, forexample, an influenza A vaccine, an influenza B vaccine, an influenza A(H1N1) vaccine, a hepatitis A vaccine, a hepatitis B vaccine, ahaemophilus influenza Type B (HiB) vaccine, a measles vaccine, a mumpsvaccine, a rubella vaccine, a polio vaccine, a human papilloma virus(HPV) vaccine, a tetanus vaccine, a diphtheria vaccine, a pertussisvaccine, a bubonic plague vaccine, a yellow fever vaccine, a choleravaccine, a malaria vaccine, a smallpox vaccine, a pneumococcal vaccine,a rotavirus vaccine, a varicella vaccine and/or a meningococcus vaccine.In other embodiments, the medicament contained within any of themedicament containers shown herein can be epinephrine. In otherembodiments, the medicament contained within any of the medicamentcontainers shown herein can be naloxone, including any of the naloxoneformulations described in U.S. patent application Ser. No. 13/036,720,entitled “Medicament Delivery Device for Administration of OpioidAntagonists Including Formulation for Naloxone,” filed on Feb. 28, 2011,the disclosure of which is incorporated herein by reference in itsentirety.

In other embodiments, the medicament contained within any of themedicament containers shown herein can include insulin, glucagon, humangrowth hormone (HGH), erythropoiesis-stimulating agents (ESA), DeMab,Interferon and other chronic therapies, or the like. Such formulationscan be produced using a general lyophilization process with glucagon (ofrecombinant origin) using bulking agents, stabilizers, buffers,acidifying agents or other excipients comprising of, but not limited to,one or more of the following combinations: lactose, hydrochloric acid;glucose, histidine, hydrochloric acid; trehalose, mannitol, citrate;trehalose, mannitol, hydrochloric acid; trehalose, glycine, hydrochloricacid; Mannitol, ascorbic acid; and Glycine, hydrochloric acid.

In other embodiments any of the injectors described herein can be filledwith and/or used to inject medicament formulations, includinglyophilized biologics and/or biopharmaceuticals, such as, for example,canakinumab, certolizumab, golimumab, and/or interleukins, for thetreatment of crypyrin associated periodic syndromes, hereditaryandioedema, and other auto-immune diseases. In yet other embodiments anyof the injectors described herein can be filled with and/or used toinject intranasal biologics, such as glucagon or human growth hormone,formulated for use in an auto injector, for the treatment ofmusculoskeletal diseases, growth disorders, diabetes & treatment relateddisorders.

In other embodiments, any of the injectors described herein can befilled with and/or used to inject an anti-thrombotics, such as LMWH,ULMWH, Xa Inhibitors, biotinylated idraparinux, etc., for either theacute management and/or surgical prophylaxis of deep vein thrombosisand/or pulmonary embolism or for the management of other conditionswhich may require anticoagulation to prevent thromboembolism, such asits use in cardiovascular diseases including atrial fibrillation andischemic stroke. In another example, in some embodiments an injectoraccording to an embodiment can be filled with and/or used to injectformulations for the treatment of asthma and/or chronic obstructivepulmonary disease.

In other embodiments, any of the injectors described herein can befilled with and/or used to inject recombinant hyaluronidase.

In other embodiments, any of the injectors described herein can befilled with and/or used to inject depot medroxyprogesterone acetate forthe treatment of infertility.

In other embodiments, any of the injectors described herein can befilled with and/or used to inject environmental, food, and householdallergen formulations for the treatment of allergic disease,specifically for use in immunotherapy.

In still other embodiments, the medicament contained within any of themedicament containers shown herein can be a placebo substance (i.e., asubstance with no active ingredients), such as water.

The medicament containers and/or medicament delivery devices disclosedherein can contain any suitable amount of any medicament. For example,in some embodiments, a medicament delivery device as shown herein can bea single-dose device containing an amount medicament to be delivered ofapproximately 0.4 mg, 0.8 mg, 1 mg, 1.6 mg or 2 mg. As described above,the fill volume can be such that the ratio of the delivery volume to thefill volume is any suitable value (e.g., 0.4, 0.6 or the like).

In some embodiments, a method includes moving a first elastomeric memberwithin a medicament container such that a medicament within a firstchamber is compressed. The medicament can be, for example, asubstantially solid medicament, such as a lyophilized medicament thatthat contains air therein. In other embodiments, the medicament withinthe first chamber can include a liquid component, and the first chambercan include air. In this manner, a portion of the air within the firstchamber can be conveyed (or purged) from the first chamber. As describedherein, in some embodiments, the air from the first chamber can beconveyed into a second chamber of the medicament container. In someembodiments, the method includes puncturing a second elastomeric memberor seal member, which defines a boundary of the second chamber such thata portion of the air within the second chamber is conveyed via theneedle to volume outside of the medicament container. In otherembodiments, the air from the first chamber can be conveyed to a volumeoutside of the medicament container.

Although the medicament containers and methods of air venting and/orpurging have been described herein as being associated with anauto-injector, in other embodiments, any of the medicament containersand methods of air venting and/or purging described herein can be usedin any suitable medicament delivery device. For example, in someembodiments, a medicament container similar to the medicament container1210 described above can be included in a pen injector, an inhaler, aninfusion device, patch-pump, or a transdermal delivery device.

In some embodiments, a method includes actuating an energy storagemember configured to produce a force on a portion of a medicamentcontainer. The portion can be, for example, a plunger (or elastomericmember) that is movable within the medicament container. In otherembodiments, the force can be exerted on a portion of the medicamentcontainer such that the portion deforms to reduce a volume within whicha medicament is stored. The application of the force is such that thevolume is reduced, thereby compressing and/or conveying air from thevolume to a volume outside of the medicament container. In this manner,any residual air within the medicament volume can be purged without theneed for the user to manually apply a purge force. Moreover, althoughthe venting and/or purging operation is described above as beinginitiated by the device being placed in a predetermined orientation, insome embodiments, the venting and/or purging can be independent from theorientation of the device.

1. An apparatus, comprising: a housing configured to contain at least aportion of a medicament container, the housing including a housingsurface defining a lock chamber; a safety member coupled to the housingand configured to be moved relative to the housing between a firstposition and a second position, the safety member configured to limitdelivery of a contents of the medicament container when the safetymember is in the first position, an outer surface of the safety memberdisposed outside of the housing, a lock protrusion of the safety memberdisposed within the lock chamber of the housing when the safety memberis in the first position, the lock protrusion disposed outside of thelock chamber when the safety member is in the second position; and alock member disposed within the lock chamber of the housing andconfigured to move along the housing surface when an orientation of thelongitudinal axis of the medicament container changes, the lock memberpositioned in contact with the lock protrusion of the safety member tolimit movement of the safety member from the first position to thesecond position when the longitudinal axis of the medicament containeris in a first orientation, the lock member spaced apart from the lockprotrusion when the longitudinal axis of the medicament container is ina second orientation.
 2. The apparatus of claim 1, wherein the safetymember is removed from the housing when the safety member is in thesecond position.
 3. The apparatus of claim 1, the lock protrusion of thesafety member defines a recessed portion configured to receive the lockmember when the longitudinal axis of the medicament container is in thefirst orientation.
 4. The apparatus of claim 1, wherein: the lockprotrusion of the safety member is one of a plurality of lockprotrusions; and the housing defines a plurality of openings, each lockprotrusion from the plurality of lock protrusions configured to bedisposed through a corresponding opening from the plurality of openingsand within the lock chamber of the housing when the lock member is inthe first position.
 5. The apparatus of claim 1, wherein: the housingsurface defining the lock chamber is angularly offset from alongitudinal axis of the medicament container, the housing surface is afirst housing surface; the housing includes a second housing surfacethat forms a nonzero angle with the first housing surface; and the lockmember is configured to move along one of the first housing surface orthe second housing surface when the orientation of the longitudinal axisof the medicament container changes.
 6. (canceled)
 7. The apparatus ofclaim 1, wherein the outer surface of the safety member is configured tobe manipulated to move the safety member from the first position to thesecond position when the longitudinal axis of the medicament containeris in the second orientation.
 8. The apparatus of claim 1, wherein thelock member has a spherical shape and is configured to roll along thehousing surface.
 9. The apparatus of claim 1, wherein: the housingsurface is a conical surface; and the lock member has a spherical shapeand is configured to roll along the conical surface of the lock chamber.10. The apparatus of claim 1, wherein: the housing surface is a firstconical surface; the housing includes a second conical surface oppositethe first conical surface that forms a nonzero angle with the firstsurface; and the lock member is configured to roll between the firstconical surface and the second conical surface when the orientation ofthe longitudinal axis of the medicament container changes. 11.(canceled)
 12. The apparatus of claim 1, further comprising: a movablemember coupled to the medicament container, the movable memberconfigured to move within housing to deliver the contents from themedicament container, the movable member including a retention portionengaged with the safety member to limit movement of the movable memberwhen the safety member is in the first position.
 13. The apparatus ofclaim 1, wherein the safety member defines a volume within which aportion of the housing is contained when the safety member is in thefirst position.
 14. The apparatus of claim 1, wherein: the medicamentcontainer is coupled to a delivery member through which the contents aredelivered, the delivery member being aligned with the longitudinal axis;and the longitudinal axis and an upward vertical axis form angle ofbetween about 25 degrees and −25 degrees.
 15. (canceled)
 16. (canceled)17. An apparatus, comprising: a housing configured to contain at least aportion of a medicament container; an energy storage member disposedwithin the housing, the energy storage member configured to produce aforce to convey a contents of the medicament container when the energystorage member is actuated to release a potential energy stored therein;and a safety member coupled to the housing, a first portion of thesafety member configured to actuate the energy storage member when thesafety member is moved relative to the housing between a first positionand a second position, a second portion of the safety member configuredto engage a lock member within the housing to limit movement of thesafety member from the first position to the second position when thelongitudinal axis of the medicament container is in a first orientation,the second portion of the safety member spaced apart from the lockmember when the longitudinal axis of the medicament container is in asecond orientation.
 18. The apparatus of claim 17, further comprising:the lock member configured to move within the housing when anorientation of a longitudinal axis of the medicament container changes.19. The apparatus of claim 17, further comprising: the medicamentcontainer, the medicament container including a first elastomeric memberand a second elastomeric member, the first elastomeric member disposedwithin a proximal end portion of the medicament container and defining,at least in part, a first volume containing a first substance, thesecond elastomeric member disposed distally from the first elastomericmember, the second elastomeric member, the first elastomeric member, anda portion of the medicament container collectively defining a secondvolume containing a second substance, the contents of the medicamentcontainer including a gas from the second volume.
 20. The apparatus ofclaim 19, wherein the first substance is a liquid diluent and the secondsubstance is a lyophilized medicament.
 21. The apparatus of claim 20,wherein the lyophilized medicament includes glucagon.
 22. The apparatusof claim 17, wherein the energy storage member is a first energy storagemember, the first energy storage member being any of a gas container, achemical energy storage member, a spring, or an electrical energystorage member, the force is a first force, the potential energy is afirst potential energy, the contents are a first contents, the apparatusfurther comprising: a second energy storage member configured to producea second force to convey a second contents of the medicament containerwhen the second energy storage member is actuated to release a secondpotential energy stored therein; and an actuator configured to actuatethe second energy storage member when the actuator is moved relative tothe housing, the safety member configured to limit movement of theactuator when the safety member is in the first position.
 23. (canceled)24. The apparatus of claim 19, further comprising: a mixing protrusiondisposed within the housing, at least a portion of the force produced bythe energy storage member exerted by the mixing protrusion onto thefirst elastomeric member to convey the contents of the medicamentcontainer.
 25. The apparatus of claim 17, wherein the housing includes ahousing surface defining at least a portion of a lock chamber, thehousing surface being angularly offset from a longitudinal axis of themedicament container, the apparatus further comprising: the lock memberdisposed within the lock chamber of the housing and configured to movealong the housing surface when the orientation of the longitudinal axisof the medicament container changes, the lock member positioned incontact with a lock protrusion of the safety member to limit movement ofthe safety member from the first position to the second position whenthe longitudinal axis of the medicament container is in the firstorientation, the lock member spaced apart from the lock protrusion whenthe longitudinal axis of the medicament container is in the secondorientation, and the lock protrusion of the safety member defines arecessed portion configured to receive the lock member when thelongitudinal axis of the medicament container is in the firstorientation.
 26. (canceled)
 27. (canceled)
 28. An apparatus, comprising:a safety member configured to be coupled to a housing of a medicamentdelivery device, the safety member configured to be moved relative tothe housing between a first position and a second position, a lockportion of the safety member configured to be disposed within a lockchamber defined by the housing when the lock member is in the firstposition, the lock portion configured to engage a lock member within thelock chamber to limit movement of the safety member from the firstposition to the second position when a longitudinal axis of the housingis in a first orientation, the lock portion spaced apart from the lockmember when the longitudinal axis of the medicament container is in asecond orientation, an actuation portion of the safety member configuredto actuate an energy storage member of the medicament delivery devicewhen the safety member is moved from the first position to the secondposition, the energy storage member configured to produce a force toconvey a contents from a medicament container of the medicament deliverydevice when the energy storage member is actuated.
 29. The apparatus ofclaim 28, wherein: the safety member is removed from the housing whenthe safety member is in the second position; and the lock portion of thesafety member includes as curved surface configured to receive the lockmember when the longitudinal axis of the medicament container is in thefirst orientation.
 30. (canceled)
 31. The apparatus of claim 28,wherein: the lock portion includes a plurality of lock protrusions, eachlock protrusion from the plurality of lock protrusions configured to bedisposed through a corresponding opening from a plurality of openingsdefined by the housing and within the lock chamber of the housing whenthe safety member is in the first position; and the plurality of lockprotrusions collectively define a volume within which the lock member isdisposed when the safety member is in the first position and when thelongitudinal axis of the medicament container is in the firstorientation.
 32. (canceled)
 33. The apparatus of claim 28, wherein themedicament delivery device is any one of a single-use auto-injector, areusable auto-injector, a pen injector, or an inhaler.
 34. The apparatusof claim 28, wherein: the medicament delivery device is a medicalinjector having a needle through which the contents from the medicamentcontainer is conveyed; and a needle sheath engagement portion of thesafety member configured to be coupled to a needle sheath covering theneedle when the needle sheath engagement portion is in the firstposition, the needle sheath engagement portion configured to remove theneedle sheath from about the needle when the safety member is moved fromthe first position to the second position.
 35. (canceled)
 36. (canceled)37. The apparatus of claim 28, wherein the safety member includes a sidewall defining an internal volume, the side wall surrounding an endportion of the housing of the medicament delivery device when the safetymember is in the first position. 38.-66. (canceled)